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More than one million people suffer from human immunodeficiency virus (HIV) 
infections in the United States. Recently, HIV treatments have been developing and 
improving steadily. Seeing this, persons living with HIV (PLWH) now live longer, but 
they can also have more chances to experience comorbid conditions. As a result, this 
dissertation study has two aims.  
Aim 1 is a longitudinal retrospective cross-sectional study to investigate the 
relationships of retention in care measurements, association with symptom burden and 
retention in care, and association between disease control and retention in care between 
PLWH with diabetes (DM).  
Aim 2 is a longitudinal retrospective comparison study to compare the chronic 
kidney disease (CKD) occurrences between PLWH and PLWH+DM from 2006 through 
2015, and to compare the survival rates differences among PLWH, PLWH+DM, and 
PLWH+DM with CKD.  
 viii 
In Aim 1, a total of 798 samples who had PLWH+DM in 2015 participated in this 
study. Most of the retention in care in PLWH+DM measurements were significantly 
correlated (p < 0.05). As to disease control, only CD4 cell count had relationships with 
retention in care measurements in all age groups, and hemoglobin A1c (HbA1c) level 
only occurred as a significant relationship with younger adults living with HIV with DM 
(YALWH+DM). Having the additional burden of some symptoms negatively affects 
retention in care in older adults living with HIV with DM (OALWH+DM).  
In Aim 2, a total of 10,063 samples had HIV infections in study. With having 
more comorbid conditions as well as increasing age at initial clinic visit, mortality rates 
increased. The mean survival time was 19.689 years (95% CI: 19.572-19.806). Having 
DM with PLWH, the mortality rates were three times higher than PLWH-only, and as for 
patients having DM with CKD in PLWH, the mortality rate was three times higher than 
PLWH+DM. 
According to the study, retention in care in PLWH+DM affects disease control 
and symptom burden (fatigue, sadness, memory loss) negatively in regard to the retention 
in care in OALWH+DM. Moreover, comorbid conditions have negative association with 
length of survival. Based on these findings, this study will contribute to the knowledge of 
comorbid conditions in PLWH as it applies to nursing practice, research, and policy.  
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  1 
Chapter One: Introduction 
This chapter will present the introduction of the study. It contains the study’s background; 
the significance of persons living with human immunodeficiency virus (HIV) (PLWH), PLWH 
with diabetes (DM), and PLWH with chronic kidney disease (CKD); the conceptual model, major 
concepts and definitions related to the study; assumptions for the summary; and limitations. 
HIV IN AMERICA 
Current HIV Trends in the United States of America 
PLWH are individuals who are infected with the HIV (AIDS Info, 2016e). The HIV 
infection causes an impaired immune system (AIDS Info, 2016e) because the virus destroys CD4 
cells (T cells), which are white blood cells key in fighting infections (AIDS Info, 2016e). 
Researchers identified HIV more than 30 years ago in 1983 (AIDS Info, 2016d). More than 1.2 
million people live with HIV (CDC, 2017b) and 50,000 patients are newly HIV-infected each year 
in the United States (CDC, 2016). Moreover, an estimated 12.8% (156,300) are not unaware of 
their HIV infection (AIDS Info, 2016d).  
The U.S. Centers for Disease Control and Prevention (CDC) created a 3 stage classification 
system based on CD4 cell count levels, which measures immune system function: Stage 1—CD4 
cell count greater than or equal to 500 cells/µL; Stage 2—200-499 cells/µL; and Stage 3—less 
than 200 cells/µL (Castro et al., 1993). Stage 3, or diagnosis of acquired immunodeficiency 
syndrome (AIDS) leads to other infections caused by the HIV infection (AIDS Info, 2016e). If it 
is not treated for appropriately, HIV infections can progress to stage 3 (CDC, 2016), which is at 
that point called AIDS (Castro et al., 1993). The survival rate for someone diagnosed with stage 
3, or AIDS is only three years (AIDS Info, 2016e) and cannot reverse damage to immune systems. 
The CDC estimated that of there are 44,073 people was diagnosed HIV; among them, 20,786 
people progressed to AIDS in 2014 (CDC, 2016).   
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Before development of HIV/AIDS treatments, the CDC in 1981 estimated that almost 
658,507 people died due to AIDS (CDC, 2016). In the mid of 1990s, HIV/AIDS treatments 
developed significantly, particularly combined antiretroviral therapy (cART) (Arts, & Hazuda, 
2012). The survival rates of PLWH increased significantly in the late 1990s (CDC, 2017a; 
Oppenheim, 2009), and now, more than 80% can live ten years after seroconversion (Oppenheim, 
2009). cART contributes to improved immune function, increases CD4 cell count, and sustains a 
low viral load (VL) (Autran et al., 1997; Mahy, Autenrieth, Stanecki, & Wynd, 2014; Mpondo, 
2016). VL indicates the amount of HIV in a patient’s body, and evaluating the amount of VL helps 
to assess health status and evaluate the effectiveness of cART (AIDS Info, 2015b). The general 
population does not have VL, but if people have an HIV infection, they have VL in their bodies 
(AIDS Info, 2015b). VL suppression is important to PLWH because if PLWH sustained VL 
suppression, they can prevent HIV progression to stage 3 (AIDS) and reduce the HIV transmission 
(AIDS Info, 2015b), VL suppression is defined of PLWH who already adhere to cART, having at 
least one an undetectable VL more than three months apart within one year (Nosyk et al., 2014). 
Having cART thus prevents the progress of HIV (Winston & Underwood, 2015). As a result of 
the development of cART, we can currently expect the life expectancy of PLWH to reach the early 
70s if patients are prescribed the correct medication and adhere to a cART regimen (Samji et al,, 
2013).   
HIV TREATMENTS 
Since 1996, the main treatment for PLWH has been cART (Arts, & Hazuda, 2012). Highly 
active antiretroviral therapy (HARRT) or cART, therapy drastically reduced HIV-related 
morbidity and mortality rates (Mahy et al., 2014; Mpondo, 2016) by preventing the progress of 
HIV disease (Winston & Underwood, 2015). Since cART has been implemented, HIV infection 
is considered a chronic condition and a manageable disease (Braithwaite et al., 2005; Winston & 
Underwood, 2015). By 2015, approximately 15 million people achieved life saving after cART 
(Joint United Nations Programme on HIV/AIDS, 2013).  
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There is debate on the initiation of treatment. According to the U.S. Department of Health 
and Human Services (HHS) Guidelines, cARTs are recommended to all PLWH regardless of any 
CD4 cell count level (HIV/AIDS Bureau, 2014). The other point of view is the WHO guidelines 
recommend that cART be initiated for CD4 cell count of less than 500 cells per µL in PLWH 
(World Health Organization, 2015). Both of the guidelines indicated that it is important to receive 
cART in PLWH. This occurs because having early retention in care is one of the improvements in 
managing HIV (Geng et al., 2010), which results in positive health outcomes (Horstmann, Brown, 
Islam, Buck, & Agins, 2010; Mugavero, Amico, et al., 2012; Mugavero, Davila, Nevin, & 
Giordano, 2010). 
There are six drug classifications in cART: non-nucleoside reverse transcriptase inhibitors 
(NNRTIs; non-nucleoside reverse transcriptase inhibitor); nucleoside reverse transcriptase 
inhibitors (NRTIs; nucleoside reverse transcriptase inhibitors); protease inhibitors (PIs; block HIV 
protease); fusion inhibitors (block HIV from entering the CD4 cells), CCR5 antagonist (CCR5s; 
block proteins on the CD4 cells); and integrase strand transfer inhibitors (INSTIs; block HIV 
integrase) (AIDS Info, 2015a). The current HHS guidelines recommend using cART mixed more 
than two different classification medications in PLWH (AIDS Info, 2016c).    
HIV DISEASE CONTROL: CD4 CELL COUNT AND VL 
HIV control and disease progression is monitored through two laboratory values: CD4 cell 
count and VL (Ford et al., 2015). First, CD4 cell count is a type of white blood cell that plays a 
key role in fighting infections (AIDS Info, 2016b). The higher the CD4 cell count, the better one 
can fight infection (AIDS Info, 2016b). Low CD4 cell count has been associated with disease 
progression treatments, cART leads to an increase in CD4 cell count or CD4 recovery (Ellis et al., 
2011). It is important to monitor a patient’s CD4 cell count every four to six months in order to 
monitor the efficacy of cART (Ford et al., 2015). The general population have a CD4 cell count 
from 500 cells/µL to 1,600 cells/µL (AIDS Info, 2016b). The target CD4 cell count in PLWH 
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should increase 50 to 100 cells/µL per year for adequate management, which indicates competent 
management of HIV infections (AIDS Info, 2016c). 
VL is a laboratory value that measures the level HIV virus in a blood sample (AIDS Info, 
2015b). Having a high VL means having more HIV infections and it indicates that the immune 
system is not working well (AIDS Info, 2015b). The medical goal is to have an undetectable VL 
means the virus is barely detectable by laboratory analysis and decreases the likelihood that the 
HIV virus will be transmitted (AIDS Info, 2015b). National HIV/AIDS strategy set a goal of 80% 
of PLWH will have an undetectable VL (White House Office of National AIDS Policy, 2015). 
PLWH who have low VL, are referred to PLWH as, having VL suppression, but it does not mean 
that HIV is cured (AIDS Info, 2016a). PLWH can achieve VL suppression by taking HIV 
medications (cART) every day and exactly as prescribed (AIDS Info, 2016a).  
BACKGROUND AND SIGNIFICANCE 
This study is significant because if focuses on (1) health outcomes of the growing segment 
of PLWH, the older adults (OA) with HIV, (2) comorbid conditions in PLWH, and (3) the HIV 
treatment cascade.  
Focus on OALWH 
According to previous studies, OA living with HIV (OALWH) are considered to be those 
over 50 years old, which which is often called older age (Emlet, 2006; Legarth et al., 2016; Savasta, 
2004; Webel et al., 2014). In the general public, OA is usually set five years later at 55 in previous 
studies (Omvik, Pallesen, Havik, Kvale, & Nordhus, 2006; Petry, 2002), however for PLWH the 
younger threshold is due to premature aging caused by chronic inflammation and activated 
immune response (Nasi et al., 2016). Due to this prolonged life expectancy, the population of OA 
with HIV is growing notably (Effros et al., 2008) compare with the pre-cART. The prevalence of 
OALWH increased steadily, from 19% to 25%, between 2001 and 2007 (Operskalski, Mosley, 
Busch, & Stram, 1997), and they make up 17% of PLWH in 2014 (CDC, 2017c). 
  5 
OALWH have different characteristics than younger adults living with HIV (YAPLWH). 
In particular, a lack of adequate social supports (living alone, health insurance status) and age-
related comorbid conditions exist (Emlet & Farkas, 2002). Only 23.3% of YALWH lived alone, 
while 36.0% of OALWH lived alone (Emlet & Farkas, 2002). Approximately 42.3% of OALWH 
had private insurance compared with only 35.6% of YALWH (Emlet & Farkas, 2002). Nearly 
30% of OALWH had more than two chronic conditions (Negin et al., 2012). 
Almost forty-two percent of OALWH in the United States died in 2013 (CDC, 2014a). 
Mortality in OALWH is related to age-related comorbid health conditions rather than being 
directly attributable to HIV infection (Braithwaite et al., 2005). This indicates that taking care of 
OALWH with comorbid conditions is important to positive health outcomes. For these reasons, 
age-related research studies for HIV-infected OA in the essential area of management of comorbid 
conditions are needed (Braithwaite et al., 2005; Martin, Fain, & Klotz, 2008). We thus need more 
studies on comorbid conditions in OALWH to prevent HIV progression and ultimately reduce 
HIV-related mortalities. 
Comorbid Conditions in PLWH: DM and CKD 
Due to compromised immune systems (Wooten-Bielski, 1999) and side effects of cART 
(Brown, et al., 2010; Kalra & Agrawal, 2013; Spollett, 2006), PLWH will have increased chance 
of developing age-related chronic diseases than people who do not have HIV (Mpondo, 2016; 
Negin et al., 2012; Vigouroux et al., 1999; Webel et al., 2015). Two of the most often diagnosed 
chronic conditions are DM and CKD (Brown et al., 2005; Adeel A Butt et al., 2009; Medapalli et 
al., 2012; Naicker, Rahmania, & Kopp, 2015). 
PLWH+DM 
Among PLWH, DM is the second-most common comorbid condition, and approximately 
15% of PLWH have DM (Brown et al., 2005; Butt et al., 2009; Medapalli et al., 2012). More than 
29.1 million people (9.3%) in the U.S. general population have DM (CDC, 2014b). In addition, 
DM is a leading factor in non-HIV-related deaths (Rolls, Denneny, Marcus, & O'Connell, 2014). 
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The most likely reason that PLWH have DM is the cARTs’ side effect, which is glucose 
intolerance (Brown et al., 2005; De Wit et al., 2008; Kim et al., 2011; Ledergerber et al., 2007). 
As a result of the cumulative exposure to cART, one of the cART HIV-1 protease inhibitors (PIs), 
has an adverse metabolic effect (Dagogo-Jack, 2008). It increases insulin resistance and impairs 
insulin secretion. Presently, the mechanism of PI-induced insulin resistance is not defined (Schütt, 
Zhou, Meier, & Klein, 2004), but PI inhibit the cellular glucose transport system (Hruz, Murata, 
Qiu, & Mueckler, 2002). PIs are also an activator of the insulin receptor tyrosine kinase, which 
creates insulin resistance (Cheng et al., 2004). 
DM Disease Control: HbA1c level  
Hemoglobin A1c (HbA1c) level is an indicator of metabolic control in DM (Diop et al., 
2006) because it indirectly measures glucose level over the previous three months (Nasir, 
Thevarajah, & Yean, 2010). The American Diabetes Association (ADA) endorsed the standard 
that the presence of DM is confirmed when HbA1c level is greater than 6.5% (American Diabetes 
Association, 2017) but there are no specified HbA1c level goals by age. Previous studies 
measuring the DM control in PLWH used a HbA1c cutoff level of 6.5% (Eckhardt, Holzman, 
Kwan, Baghdadi, & Aberg, 2012; Tien et al., 2012). Despite this, the HbA1c level cutoff level in 
OA without major comorbidities is 7-7.5% in the general population (Kirkman et al., 2012). Thus, 
we may accept this criterion in PLWH with comorbid conditions. But still, no gold standard 
criterion exists in PLWH+DM (Tien et al., 2012). For this study, however, the researcher used a 
HbA1c cutoff level of 6.5% because the CNICS defined DM based by this criteria. 
PLWH+CKD  
CKD is a common complication of HIV infection and is three times more likely to develop 
in PLWH than in the general population (Bonjoch et al., 2014; Ibrahim et al., 2012; Islam, Wu, 
Jansson, & Wilson, 2012; Schwartz et al., 2005). The major reason for the higher chance of 
comorbidities in OALWH could be systematic inflammation from the HIV infection and side 
effects of cART (Brown et al., 2010; Gebo & Justice, 2009; Kalra & Agrawal, 2013; Spollett, 
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2006). There are many risk factors are associated with the diagnosis of CKD in PLWH, such as 
aging, hypertension, DM, nephrotoxic drugs, and hepatitis (Bonjoch et al., 2014). But the 
development of DM in PLWH is the main cause of CKD occurrence (Estrella & Fine, 2010).  
Due to systemic inflammation, the increasing DM has become a risk factor for CKD rates 
(Hadigan et al., 2001). Proinflammatory cytokine (e.g., tumor necrosis factor [TNF]- α) can 
increase insulin resistance (Hotamisligil et al., 1996) by inhibiting insulin uptake in adipose tissue, 
skeletal muscles, and the liver contributing to an abnormal metabolic state (De Luca & Olefsky, 
2008). Insulin resistance among PLWH is higher than in the general population because of the 
cART (Carr, Samaras, Chisholm, & Cooper, 1998). One of the cART, PIs, can increase the effect 
of glucose on insulin-responsive cells (Carr et al., 1998). Thus, using certain PIs increase insulin 
resistance and also leads to DM (Brown et al., 2010).  
Having CKD in PLWH has increased morbidity and mortality rates when compared with 
PLWH without kidney disease (Adedeji et al., 2015; Kim et al., 2011; Szczech et al., 2004). End 
Stage Renal Disease (ESRD) is the end stage of renal disease, which is a reversible stage of kidney 
disease and where a transplant is needed (Bickel et al., 2013). It is one of the most common causes 
of HIV-related morbidity and mortality rates (Adedeji et al., 2015; Kim et al., 2011; Szczech et 
al., 2004). As a result, it is important to manage PLWH+DM to prevent complications, such as 
CKD. Still, no studies have examined the relationship between CKD occurrence and PLWH+DM. 
HIV Treatment Cascade 
The HIV treatment cascade, or HIV care continuum, describes the five steps for HIV care, 
which includes being diagnosed with HIV, linked to care, retention in care, prescribed cART, and 
achieved VL suppression (White House Office of National AIDS Policy, 2015). Below describe 
the five steps in detail (AIDS Info, 2017).  
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HIV Testing and Diagnosis 
This is the first step to initiate the HIV treatment cascade. We can diagnose people who 
have HIV infection through any one of these: a confirmed HIV-positive test; detectable VL; 
receiving HIV-related care; have AIDS-defining illness; or receiving cART (Nosyk et al., 2014).  
Linkage to Care 
Linkage to care is the process of engaging a newly-diagnosed person with HIV infection 
into HIV primary care. PLWH who receives HIV care service will do so within 30 days of 
diagnosis (Nosyk et al., 2014). 
Retention in Care in PLWH  
Retention in care is an essential component of positive health outcomes in PLWH (Geng 
et al., 2010). The definition of retention in care is defined as a PLWH remaining connected to 
medical care, once entered (Messeri, Abramson, Aidala, Lee, & Lee, 2002). However, retention in 
care ends at a pre-defined interval of time after a scheduled appointment (Geng et al., 2010). 
Retention in care is essential components to keep receipt of cART, evaluate medication toxicity, 
and investigate HIV treatment failure (Geng et al., 2010). The two steps in the retention in care 
include starting antivirals and evaluating retention in care.   
Prescribed Antivirals 
The three stages in prescribed antivirals include: cART indicated; prescribed cART; and 
adherence to cART (Nosyk et al., 2014). cART indicated prescribed antivirals is among PLWH 
retained in HIV care, but not currently receiving cART yet (Nosyk et al., 2014). On cART 
prescribed antivirals is PLWH with cART indicated, receiving more than two antiretroviral drugs 
more than three months apart within one year (Nosyk et al., 2014). Adherence to cART prescribed 
antivirals is among PLWH on cART, receiving at least 80% adherence within one year or initiated 
cART within one year (Nosyk et al., 2014). 
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Measuring Retention in Care  
Retention in care among individuals linked to HIV care is defined as those who received 
the CD4 cell count and VL test or received at least two antiretroviral drugs more than three months 
apart within one year (Nosyk et al., 2014). To be effective, cART works to generate immunological 
recovery and sustain virological suppression in PLWH (Alvarez-Uria, Pakam, Midde, & Naik, 
2013). One of the most important aspects of care for PLWH is to initiate cART (Kinloch, Kwong, 
Ellis, Johnson, & Smith, 2015). The common measurement of retention in care in PLWH includes: 
missed visits; visit adherence; visiting gaps in care; and visiting consistency and the Health and 
Resources Services Administration HIV/AIDS Bureau [HRSA HAB] measure) (Mugavero, 
Westfall, et al., 2012). 
A. Missed Visits 
Missed visits is defined as the number of missed visits during the course of clinic care in a 
specific time period; it includes only “no-shows,” not cancelled or rescheduled visits et al., 2010; 
Mugavero, Davila, Nevin, & Giordano, 2010; Mugavero, Westfall, et al., 2012). Many studies 
measured missed visits as a dichotomous variable (yes or no) (Magnus et al., 2010; Mugavero, 
Lin, Willig, et al., 2009; Mugavero, Westfall, et al., 2012) or a counted variable (number of missed 
visits) (Brennan, Maskew, Sanne, & Fox, 2010; Mugavero, Westfall, et al., 2012).  
B. Visit Adherence 
Visit adherence is divided into visit adherence and visit nonadherence (Mugavero et al., 
2010). Visit adherence is a proportion, with the number of visits arrived for in the numerator and 
the number of all scheduled visits (number of arrived + number of bumped + number of no-shows) 
in the denominator, and it is presented as a percentage (range: 0–100%) (Catz, McClure, Jones, & 
Brantley, 1999; Kissinger et al., 1995; Mugavero et al., 2010; Mugavero, Westfall, et al., 2012). 
C. Visiting Gaps in Care 
Visiting gaps occur when patients with an HIV/AIDS diagnosis fail to keep appointments 
for follow-up medical visits with a provider during cART. The gaps in care are measured by a time 
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interval between visit constancy, visiting gaps, and the HRSA HAB measure (Fleishman et al., 
2012; Mugavero et al., 2010; Mugavero, Westfall, et al., 2012).   
D. Visit Consistency 
Visit consistency is the proportion of at least one-time visits within the specific time 
intervals (Mugavero et al., 2010; Mugavero, Westfall, et al., 2012). As follow-up on the guidelines 
from the Panel on Antiretroviral Guidelines for Adults Adolescents (2017), the visit usually 
consists of an assessment duration range of every three to six months (Panel on Antiretroviral 
Guidelines for Adults Adolescents, 2017).  
E. HRSA HAB Measure 
The Health and Resources Services Administration HIV/AIDS Bureau developed the 
HRSA HAB measure for measuring retention in care (U.S. Department of Health and Human 
Services, 2016). The HRSA HAB measure identifies whether PLWH visited more than two times 
during 90 days within a 12-month period (Hall et al., 2012; Mugavero et al., 2010; Mugavero, 
Westfall, et al., 2012; U.S. Department of Health and Human Services, 2016). The numerator is 
the ‘number in denominator who did not have a provider visit in last 6 months of review year,’ and 
the denominator is ‘one or more medical visits in first 6 months, not deceased by the end of the 
year, incarcerated over 90 days during the year or lost to follow-up’ (Massachusetts Department 
of Public Health and The Boston Public Health Commission, 2013). This measure matches with 
the National HIV/AIDS Strategy (Health Resources Services Administration, 2008), and it 
captured appointment constancy and gaps in care (Mugavero et al., 2010), but there is a lack of 
research using the HRSA HAB measure retention in care in PLWH. 
Importance of Retention in Care 
Retention in care in PLWH is engaging medical care and attending required provider visits 
for primary HIV care (Geng et al., 2010). Retention in care has a significantly positive relationship 
with health outcomes, VL suppression, slower HIV progression, and reduced HIV transmission 
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(Giordano, Hartman, Gifford, Backus, & Morgan, 2009; Metsch et al., 2008; Mugavero et al., 
2010). 
Followed by the U.S. clinical practice guideline, one of the major important issues in the 
management of PLWH is retention in care (Panel on Antiretroviral Guidelines for Adults 
Adolescents, 2017). The U.S. clinical practice guidelines suggest that PLWH receive cART every 
three to four months (Panel on Antiretroviral Guidelines for Adults Adolescents, 2017; White 
House Office of National AIDS Policy, 2015). But according to the CDC, only 28% of people with 
HIV/AIDS have VL sustain, and 49% of people with HIV/AIDS are not engaged in constant 
retention in care (CDC, 2011b ; Gardner, McLees, Steiner, del Rio, & Burman, 2011).  
Discontinuous retention in care in PLWH is defined as those who did not receive consistent 
care for their HIV that may cause a lapse cART due to an expired prescription (Mugavero, Amico, 
et al., 2012). Discontinuous retention in care in PLWH has a negative effect on health outcomes 
as a result of high VL (Mugavero, Amico, et al., 2012). Discontinues retention in care has been 
associated with decreases in CD4 cell count and increases in VL (Berg et al., 2005; Hogg et al., 
1998; Lima et al., 2009; Mugavero, Amico, et al., 2012; Mugavero, Lin, Allison, et al., 2009; 
Tripathi, Youmans, Gibson, & Duffus, 2011; Walensky et al., 2006), which are ultimately 
significantly negative related with clinical outcomes and survival rates (Mugavero, 2008). PLWH 
having poor retention in care were two times more likely to die than those who received continuous 
retention in care (Giordano et al., 2007). 
PURPOSE OF THE STUDY 
This dissertation study has two goals. The first is a longitudinal retrospective cross-
sectional study aim (Aim 1): to investigate retention in care between PLWH+DM divided by age 
groups (OALWH, YALWH) by 1) comparing paths regarding the retention in care and disease 
control (CD4 cell count, HbA1c level) by two age groups (OALWH, YALWH), 2) investigating 
variables (demographics and symptom burden) associated with retention in care. The second aim 
is a longitudinal retrospective comparison study aim (Aim 2): to compare the short-term health 
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outcomes (CKD occurrences) between PLWH and PLWH+DM groups in 2006 through 2015, and 
to compare the long-term health outcomes (survival rates) differences among PLWH, 
PLWH+DM, and PLWH+DM+CKD groups. 
The specific aims of the dissertation are as follows: 
 
Aim 1. Describe the population of OALWH+DM who visited the CNICS clinics during 
2015.  
Research question 1: What are the differences in demographic descriptive characteristics 
(age, gender, race/ethnicity) and baseline disease control (CD4 cell count, HbA1c level) between 
OALWH+DM (> 50 years old) and YALWH+DM (≤	50 years old)?  
Research question 2: What are the differences in retention in care descriptive 
characteristics (missed visits, visit adherence, 4-month visit constancy, 6-month gap, HRSA HAB 
measure) between OALWH+DM (> 50 years old) and YALWH+DM (≤	50 years old)? 
Research question 3: What are the correlations between retention in care measurements 
(missed visits [count, dichotomous]), visit adherence, 4-month visit constancy, 6-month gap, 
HRSA HAB measure), and each other between OALWH+DM (> 50 years old) and YALWH+DM 
(≤ 50 years old)?  
Research question 4: What are the relationships between retention in care measurements 
(missed visits [count, dichotomous]), visit adherence, 4-month visit constancy, 6-month gap, 
HRSA HAB measure), and CD4 cell count between OALWH+DM (> 50 years old) and 
YALWH+DM (≤ 50 years old)?  
Research question 5: What are the differences paths in retention in care regarding HIV 
disease control (CD4 cell count) and DM disease control (HbA1c level) between OALWH+DM 
(> 50 years old) and YALWH+DM (≤	50 years old)? 
  13 
Research question 6: What are the relationships between symptom burden (HIV Symptom 
Index) and retention in care (HRSA HAB measure) between OALWH+DM (> 50 years old) and 
YALWH+DM (≤	50 years old)?  
 
Aim 2: Investigate the effect of comorbid conditions of DM and CKD on the survival rates 
of PLWH+CKD who visited the CNICS clinics from 2006 through 2015. 
Research question 1: What are the different characteristics (age, gender, race/ethnicity, 
mortality, CD4 cell count, HbA1c level) among PLWH, PLWH+DM, and PLWH+DM+CKD 
during the years 2006—2015?  
Research question 2: What is the occurrence of chronic kidney disease (CKD) among 
PLWH and PLWH+DM who visited the CNICS clinics in the years 2006—2015? 
Research question 3: What is the 10-year survival rates among PLWH, PLWH+DM, and 
PLWH+DM+CKD who visited the CNICS clinics (2006—2015)? 
CONCEPTUAL FRAMEWORK 
For this study, the author tested a conceptual model based on the study model presented by 
Mugavero, Westfall, et al. (2012) for retention in care for PLWH, which involved measuring 
retention in HIV care in all age groups. 1) Model 1 (Figure 1) views linear causal pathways among 
symptom burden, retention in care, and disease control by different age groups in PLWH+DM. 
These causal pathways explain the effect of retention in care on disease control. At each respective 
point, factors represent the samples’ characteristics and symptom burden, which are attributed to 
the retention in care, and this retention in care is in turn attributed to the disease control in different 
PLWH+DM age groups. 2) Model 2 (Figure 2) views linear causal pathways between CKD 
occurrence rate and survival rates in different disease groups. These causal pathways demonstrate 
the occurrence of CKD and survival rates among PLWH, PLWH+DM, and/or PLWH+DM+CKD. 
At each respective point, factors represent the samples’ characteristics as well as any 
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characteristics attributed to CKD occurrences and survival rates in PLWH, PLWH+DM, and/or 
PLHW+DM+CKD groups.   
The proposed conceptual model for this study consists of predictor variables and health 
outcomes. Health outcomes included both short-term and long-term effects. For Aim 1, the 
predictor variables included demographic (age, gender, race/ethnicity) and symptom burden (HIV 
Symptom Index) variables. The Aim 1 model proposed that retention in care improved disease 
control, e.g.., CD4 cell count, HbA1c level, both of which are short-term outcomes in PLWH+DM. 
Retention in care measurements included missed visits, visit adherence, visit constancy, visits 
gaps, and the HRSA HAB measure. To investigate the association between symptom burden and 
retention in care, the researcher used the HRSA HAB measure of retention. Further, the paths 
present relationships between retention in care measurements (missed visits [count], visit clinic 
attendance, visit adherence, 4-month visit constancy) and disease control (CD4 cell count, HbA1c 
level). Aim 2, the predictor variables, included demographics (age, gender, race/ethnicity), 
diagnosed disease (PLWH, PLWH+DM, PLWH+DM+CKD), age at initial CNICS clinic visits 
groups (≤	30, 31-50, > 50 years old), and disease control (CD4 cell count and HbA1c levels) 
variables; the short-term outcomes that result are HIV and DM complications (CKD occurrence). 
Long-term outcomes are survival rates among PLWH, PLWH+DM, and PLWH+DM+CKD. The 
studies tested this model using the Center for AIDS Research (CFAR) Network of Integrated 
Clinic Systems (CNICS) data set, which includes data for each of the variables presented in Figure 
1 and Figure 2. Although these two conceptual models have not yet been fully validated, their 
pathways provide a useful view of retention in care, CKD occurrence, disease controls, and 
survival rates. 
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Figure 1. (Model 1) A conceptual model of retention in care for PLWH+DM  
 
Figure 2. (Model 2) A conceptual model of CKD occurrence/survival rates for PLWH, 
PLWH+DM, and/or PLWH+DM+CKD 
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DEFINITIONS OF MAJOR CONCEPTS 
The definitions of this study are presented below. 
Acquired Immune Deficiency Syndrome (AIDS): Affliction among HIV-infected patients who 
developed stage 3 (AIDS) (CD4 cell count below 200 cells/µL) (AIDS Info, 2016e).  
CD4 cell count: The study will use three categories presented in the CDC Classification System 
for HIV-Infected Adults and Adolescents (category 1: ≥ 500 cells/µL, category 2: 200-499 
cells/µL, category 3: < 200 cells/µL) (Castro et al., 1993). 
The Center for AIDS Research (CFAR) Network of Integrate Clinic Systems (CNICS): The CNICS 
included around 32,000 HIV-infected patients over 18 years old who visited one of the following 
clinics: The University of Washington; Case Western Reserve University; University of 
California, San Francisco; University of North Carolina at Chapel Hill; Johns Hopkins University; 
Fenway Health; University of California, San Diego; or University of Alabama at Birmingham. 
The CNICS included data from 1998 to 2015. 
Chronic kidney disease (CKD): People who were diagnosed with CKD by the CNICS using the 
CKD-EPI equation.  
Diabetes (DM): People who were diagnosed with DM by the CNICS (HbA1c level over 6.5% 
and/or have DM medications). 
Diabetes (DM) disease control: HbA1c level is used to determine disease control in DM patients 
(Inada, Oishi, Nishikawa, Kurata, & Imura, 1980). 
Older adults living with HIV (OALWH): People over 50 years old people who are HIV-infected 
(Emlet, 2006; Legarth et al., 2016; Savasta, 2004; Webel et al., 2014).   
End Stage Renal Disease (ESRD): The last stage of chronic kidney disease at which people need 
to initiate renal replacement therapy (Bickel et al., 2013).  
Hemoglobin A1c (HbA1c) level: The HbA1c level reflects the average blood glucose level during 
the previous two to three months (Hanas & John, 2010).  
HIV-associated nephropathy (HIVAN): Kidney disease associated with HIV infection (Winston, 
Burns, & Klotman, 1998). 
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HIV disease control: The CD4 cell count is the major disease-control measurement in HIV-
infected people (AIDS Info, 2016c). 
HIV Symptom Index: 20-items (fatigue, fever, dizzy, neuropathy, forgetful, nausea, diarrhea, sad, 
anxious, sleep problems, skin problems, coughing, headache, loss appetite, bloating, muscle aches, 
sex problems, body fat, weight loss, hair loss) with five response choices—0: I do not have the 
symptom, 1: I have the symptom, but it does not bother me, 2: I have the symptom, but it bothers 
me little, 3: I have the symptom, and it bothers me some, 4: I have the symptom, and it bothers me 
a lot (Justice et al., 2001).  
HIV treatment cascade care: Five steps for improving HIV care (diagnosed, linked to care, 
retention in care, prescribed antiretroviral therapy, and achieved VL suppression) (AIDS Info, 
2017). 
Mortality/Survival rates: Mortality ascertainment refers to people who have death records from 
the CNICS clinics, the National Death Index (NDI) and death certificate data (ICD-9 and ICD-
10). Mortality rates/Survival rates were calculated as number of deaths per 100 person-years 
during 10-years (2006-2015). 
Persons living with human immunodeficiency virus (PLWH): People who are infected with human 
immunodeficiency virus (CDC, 2017c). 
Retention in care measurement: This measured six retention in care methods (missed visits [count, 
dichotomous], visit adherence, 4-month visit consistency, 6-month visit gap, and the HRSA HAB 
measure) (Mugavero, Westfall, et al., 2012). 
• Missed visits: Counting the number of no-shows (Mugavero, Westfall, et al., 2012). 
• Missed visits: Dichotomous variable (0: Always show, 1: more than one time no show) 
(Mugavero, Westfall, et al., 2012). 
• Visit adherence: Number of arrived/Number of arrived + Number of bumped + Number of no-
shows (Mugavero, Westfall, et al., 2012). 
• Four-month visit consistency: Measuring four-month visit consistency (0: no 4-month visit, 1: 
presented 4-month visit) (Mugavero, Westfall, et al., 2012). 
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• Six-month visit gap: Measuring six-month visit gap (0: presented gap ≤ 188 days, 1: presented 
gap ≥ 189 days) (Mugavero, Westfall, et al., 2012). 
• HRSA HAB measure: Had two kept visits separated by more than 90 days during the one year 
(0: not retained; 1: retained 90-days gap) (Mugavero, Westfall, et al., 2012; U.S. Department 
of Health and Human Services, 2016). 
Younger adults living with HIV (YALWH): People aged 50 and under 50 years and older who are 
HIV-infected.   
Viral load (VL): Viral load is testing how many HIV-related virus particles exist in a milliliter of 
a person’s blood; people without HIV do not have viral load (U.S. Department of Health and 
Human Services, 2016). 
ASSUMPTIONS 
There are several assumptions for this study: 
1. Data entry from the CNICS occurred without errors. 
2. The conceptual frameworks are an appropriate framework to answer the research 
questions. 
3. All participants in this study answered questions honestly and accurately. 
LIMITATIONS 
This study has several limitations: 
1. The study findings are limited to the CNICS participants. Thus, it could have 
generalization problems. 
2. This study’s Aim 1 only considered the one-year observation period in 2015. Thus, it 
may not have been systematically captured.  
3. This study’s Aim 1 exclude the people who died during the one-year observation period 
from the primary analysis. 
4. This study has missing data, which the author excluded. Thus, it could have bias. 
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SUMMARY 
This chapter explained the background and significance of retention in care in HIV and 
survival rates in PLWH with comorbid conditions. This study has two aims. Aim 1 seeks to 
investigate retention in care measurements in PLWH+DM divided by different age groups, to 
define path differences in disease controls (CD4 cell count, HbA1c level) divided by different age 
groups in PLWH+DM, and to demonstrate symptom burden and retention in care in OALWH+DM 
and YALWH+DM. Aim 2 is to find the occurrence of CKD in two different groups (PLWH, 
PLWH+DM), and to investigate survival rates among PLWH, PLWH+DM, and 
PLWH+DM+CKD groups. Chapter Two will present the literature review. Chapter Three will 
present the Aim 1 study, and Chapter Four will present the Aim 2 study. Finally, Chapter Five will 
present the discussion, conclusions, and implications.  
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Chapter Two: Literature Review 
In this chapter will present the overall literature review based on the Aims. This literature 
review will examine current research linking 1) retention in care in older adults (OA) living with 
human immunodeficiency virus (HIV) (LWH) with diabetes (DM), and 2) chronic kidney disease 
(CKD) occurrence and survival rates in PLWH. This review will provide a brief overview of 
OALWH. Next, it will describe retention in care and health outcomes in persons living with HIV 
(PLWH), comorbid conditions in PLWH+DM, a systematic review of CKD occurrence in PLWH. 
Lastly, it will describe the survival rates in PLWH. 
OAPLWH 
The number of OAPLWH is increasing (Mahy et al., 2014) from 17 % in 2001 and 31% of 
OA people (over 50) in 2008 had HIV infection (CDC, 2005, 2011a). About 30.4% OA diagnosed 
HIV infection after 50 years old (Paul, 2007). The OA population is vulnerable to acquiring HIV 
infection (Fox & Rosen, 2010; Micek et al., 2009). The OA have less knowledge of HIV/AIDS 
infections and sexually transmitted diseases (STDs) than younger people, so HIV/AIDS spread 
easily to the OA (Paul, 2007). Once diagnosed, OALWH have a higher chance of AIDS 
progression when compared to younger adults living with HIV (YALWH) (Barth, van der Loeff, 
Schuurman, Hoepelman, & Wensing, 2010; Rosen & Fox, 2011). Due to the decreased tendency 
for OA to test HIV/AIDS, so OALWH tend to undergo HIV treatments that started later (Paul, 
2007). Thus, 50% of OALWH progress to acquired immunodeficiency syndrome (AIDS), which 
is the third stage of HIV infection, in less than one year from diagnosis (Martin et al., 2008). Also, 
there are racial/ethnic disparities in the HIV incidence rate among OALWH. The chance of HIV 
infection in OA is twelve times higher in African Americans and five times higher in Hispanics 
than in Whites (Kirk & Goetz, 2009).  
Overall, with improved treatment, the OALWH population is steeply growing, and they 
have complex medical management. OA tend to have more comorbid conditions and late HIV 
diagnoses, and due to those late diagnoses, they have had more of a chance for disease progression 
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(AIDS), which is significantly correlated with mortality rates. Although OALWH need more focus 
care, limited studies exist in OALWH population. 
Barriers to Care in OALWH 
There are some barriers to HIV care in OALWH. First, it remains hard to diagnose an HIV 
infection in OALWH because the early symptoms of HIV are similar to aging, such as decreased 
immune system, fatigue, weight loss, loss of appetite, and memory loss (Simone & Appelbaum, 
2008). Moreover, doctors commonly do not think OA are at risk of contracting HIV/AIDS (Myers, 
2009; Schmid et al., 2009) because one of the main risk factors for transmission is being sexually 
active, and doctors’ believe OA are not as sexually active as younger people (Lindau et al., 2007; 
Paul, 2007). However, OALWH, however, are more vulnerable to infection. Aging makes the 
immune system weaker, and a weak immune system is not able to fight off infections as well 
(Wooten-Bielski, 1999). Thus, with a weak immune system, OALWH rapidly progresses to AIDS 
(Wooten-Bielski, 1999) and causes death (Kirk & Goetz, 2009). It is therefore important to identify 
the HIV infection and AIDS early because effective combined antiretroviral therapy (cART) will 
give OALWH a chance at a longer life because the initiation of cART contributes to lower 
mortality rates (Moyer, 2013). 
In summary, review articles on barriers to care in OALWH have stated that there are many 
barriers to care for this population. OA are hard to diagnose in the initial stage of HIV infections 
due to similar symptoms of aging. Because of this, OA have a delayed age at initial CNICS clinic 
visit, which makes them have higher mortality rates (Kirk & Goetz, 2009) due to disease 
progression (Wooten-Bielski, 1999). Despite the importance of taking care of OALWH, not many 
studies have focused on this population. To explore ways to improve OA’s HIV care, researchers 
need to conduct more studies on OALWH that consider their special circumstances. 
RETENTION IN CARE AND HEALTH OUTCOMES IN PLWH 
Retention in care in PLWH is a priority for health care providers (Crawford, Sanderson, & 
Thornton, 2013). Retention in care in PLWH is quite important because it relates to positive health 
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outcomes; sustain viral load (VL), control CD4 cell count, and protect to HIV progression 
(Horstmann et al., 2010; Mugavero, Amico, et al., 2012; Mugavero et al., 2010). This becomes 
significantly important because it contributes to maximizing VL suppression, reducing HIV/AIDS 
progression, and decreasing HIV transmission (Giordano et al., 2009; Metsch et al., 2008; 
Mugavero et al., 2010). 
CDC guideline recommended that HIV-afflicted patients receive cART following visits 
every three to four months (Panel on Antiretroviral Guidelines for Adults Adolescents, 2017). 
Nonetheless, the Yehia et al. (2012) outpatients study indicated that 58.4% PLWH had visiting 
gaps (N = 17,425). Among them, 31.1% PLWH had at least visiting gaps in care, in visits during 
seven to twelve months, and 27.7% had more than one visiting gap longer than one year (Yehia et 
al., 2012). Moreover, 27.2% participants did not visit at least one quarter (Yehia et al., 2012). Also, 
57.4% participants did not meet the Health and Resources Services Administration HIV/AIDS 
Bureau (HRSA HAB] measure criterion during their outpatient time (Yehia et al., 2012). Sixty 
percent of PLWH had missed visit within one year (Mugavero, Lin, Willig, et al., 2009). Having 
missed visits within one year after initiated cART, the mortality rate was twice higher than who 
did not missed at all (p < 0.02) (Mugavero, Lin, Willig, et al., 2009). In addition, the missed visits 
were associated with the hazards of mortality (hazard ratio [HR]: 2.90, 95% confidence interval 
[CI]: 1.28-6.56). This low retention in care have possible reasons due to uninsured, substance 
abuse, and mental illness (Mugavero, Lin, Willig, et al., 2009). 
Measuring retention in care can be done by calculating visiting times and visiting intervals 
(Mugavero, Westfall, et al., 2012). Even so, several studies have suggested that the standard of 
retention in care in PLWH would include missed visits, visit adherence, visit constancy, visiting 
gaps, and the HRSA HAB measures (Health Resources Services Administration, 2008; Mugavero 
et al., 2010; Mugavero, Westfall, et al., 2012; Yehia et al., 2012). Among 10,053 participants, all 
of the six retention in care measurements associated significantly with missed visits (odds ratio 
[OR] 0.73, 95% CI: 0.71-0.75), visit adherence (OR: 3.9, 95% CI: 3.5-4.3), visit constancy (OR: 
  23 
2.8, 95% CI: 2.5-3.0), visiting gaps (OR: 3.0, 95% CI: 2.6-3.3), and the HRSA HAB measure (OR: 
3.8, 95% CI: 3.3-4.4) (Mugavero, Westfall, et al., 2012). 
In sum, the previous studies demonstrated that retention in care is one of the key 
components (Geng et al., 2010) to positive health outcomes in PLWH (Horstmann et al., 2010; 
Mugavero, Amico, et al., 2012; Mugavero et al., 2010). Many studies did not use the same methods 
to measure retention in care in PLWH, but, usually, studies commonly used missed visits, visit 
adherence, visit constancy, and visiting gaps to measure retention in care in PLWH. However, in 
addition to the importance of retention in care in PLWH, previous studies indicated that we need 
to take care of OALWH who have comorbid conditions. However, there are no studies regarding 
retention in care of OALWH with comorbid conditions, including DM and CKD. In sum, 
healthcare professionals need more research on retention in care in OALWH who have comorbid 
conditions. 
COMORBID CONDITIONS IN PLWH +DM 
Having comorbid conditions depend on age, HIV stage, and severity (CD4 cell count, VL) 
(p < 0.001) (Goulet et al., 2007). Sixty percent of PWLH (N = 33,420) had at least one comorbid 
condition (p < 0.001) (Goulet et al., 2007). Another study indicated that 60% of OALWH who 
were over 50 have a comorbid condition (Rolls et al., 2014). The Goulet et al. (2007) study is a 
large cohort study that compared comorbid conditions among veterans (HIV infection n = 33,420, 
without HIV infection n = 66,840). The most frequent comorbid conditions were hypertension 
(20%), DM (8%), vascular diseases (6%), liver diseases (13%), and renal diseases (3%) (p < 0.001) 
in PLWH (Goulet et al., 2007). Also, PLWH had increased chances to have comorbid conditions 
of renal, vascular, and pulmonary diseases than the population without HIV infection (Goulet et 
al., 2007). Additionally, 31% of PLWH were OA and they have more multimorbidity conditions 
than OA without HIV infections (p < 0.001) (OR: 1.17, 95% CI: 1.02-1.33) (Goulet et al., 2007). 
In the Magalhães, Greenberg, Hansen, & Glick (2007) study, 88.8% (N = 162) OALWH had at 
least one comorbid condition; 18% PLWH had one comorbid condition, 27.8% had two, and more 
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than a half-percent of people had more than three comorbid conditions. Further, aging and HIV 
infection were significantly close relationships on DM occurrence (OR: 1.12, 95% CI: 1.02-1.03), 
vascular diseases occurrence (OR: 1.12, 95% CI: 1.00-1.24), and liver diseases occurrence (OR: 
1.29, 95% CI: 1.16-1,44) (Goulet et al., 2007). Through the previous studies, we can ascertain that 
most OALWH had comorbid conditions. The need exists to focus on DM because it is one of the 
primary comorbid conditions occurring in OALWH (Vance, Mugavero, Willig, Raper, & Saag, 
2011). The most frequent comorbid conditions according to the Goulet et al. (2007) study, 
hypertension, and DM is the major risk factor of occurring hypertension. Incidentally, the medical 
field regards DM  as a chronic disease that is defined as manageable (Ross, 2004). The most 
important reason to express concern about DM is that chronic diseases correlate highly with non-
HIV-related death rates (Braithwaite et al., 2005), so by addressing DM in PLWH, we can expect 
an improvement in health outcomes in PLWH. However, previous studies have not evaluated and 
compared PLWH and PLWH+DM. Therefore, we need to conduct research on comorbid 
conditions, especially on DM in PLWH, to define their unique characteristics.     
 
PLWH+DM 
With expanded access to cART today, the prevalence of PLHW with DM as a comorbid 
condition is increasing (Isa et al., 2016); for instance, 5% of 1,000 people who received cART 
have DM (Riyaten et al., 2015). The mortality rate of PLWH+DM was 24.4% within a 95% 
CI = 4.46–5.00 (p < 0.05) in 1991 through 2011 (Moreira et al., 2016). HIV with cART carries a 
risk factor of DM (Brar, Shuter, Thomas, Daniels, & Absalon, 2007; De Wit et al., 2008; Galli et 
al., 2012; Isa et al., 2016; Samaras, 2009; Shen et al., 2013). HIV infection causes insulin resistance 
and peripheral lipodystrophy (Rudich, Ben-Romano, Etzion, & Bashan, 2005). cART includes 
protease inhibitor (PI) medications such as tenofovir, which causes insulin resistance and 
dyslipidemia (Grinspoon & Carr, 2005; Rudich et al., 2005; Samaras, 2009), which prevents the 
uptake of glucose and interferes with adipogenesis, adipocytes, and hepatocytes (Rudich et al., 
2005). Further, having DM is closely related with aging, just as it is in the general population (Brar 
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et al., 2007). In a large cohort study in PLWH, the prevalence of DM in PLWH baseline was 2.3% 
(Isa et al., 2016), and it is closely related with aging. The incidence of DM when they received 
cART was 5.3%–6.0% (Dever, Oruwari, Figueroa, O'Donovan, & Eng, 2000; Isa et al., 2016). 
About 5.3% had newly diagnosed DM after received cART for one year (95% CI, 4.2%-6.3%) 
(Isa et al., 2016). 
Empirical research has demonstrated that, due to aging, HIV infection, and HIV treatments, 
PLWH are more likely to develop DM. DM is one of the most common chronic diseases in PLWH, 
and having a chronic disease is a major non-HIV-induced reason for death in PLWH (Braithwaite 
et al., 2005). Having more comorbid conditions causes patients to carry more of symptom burden 
and results in negative health outcomes in PLWH (Gay et al., 2011; Gonzalez et al., 2007; Harding 
et al., 2012; Holzemer, Hudson, Kirksey, Jane Hamilton, & Bakken, 2001; World Health 
Organization, n.d.). The settings and populations in previous studies were very limited, however, 
and few studies demonstrated the prevalence of DM in PLWH, and there are no comparison studies 
in PLWH and DM. For future studies, we need to focus on the comparison between PLWH and 
PLWH+DM based on their different characteristics and a focus on their health outcomes.  
THE PREVALENCE OF CHRONIC KIDNEY DISEASE IN PERSONS LIVING WITH HIV: A 
SYSTEMATIC REVIEW 
Abstract 
Objective: A systematic review of the research on chronic kidney disease (CKD) in persons living 
with human immunodeficiency virus (HIV) (PLWH), in order to (1) examine studies’ 
characteristics, (2) define estimated glomerular filtration rate (eGFR) used to determine CKD, (3) 
identify risk factors for CKD, and (4) investigate CKD’s prevalence in PLWH.  
Methods: Keyword searches of the PubMed and PsycInfo databases and manual searches of 
references for 2000 through 2016, following PRISMA guidelines. Articles that presented the 
prevalence of CKD in people with HIV were selected.  
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Results: Twenty-one studies met inclusion criteria. The prevalence of CKD in those with HIV 
ranged from 2.3% to 53.3% across a variety of countries. The most common equation for obtaining 
eGFR was modification of diet in renal disease (MDRD), and most articles used the CKD criterion 
of eGFR < 60 mL/min/1.73 m2 and/or presence of protein in the urine. Major risk factors for CKD 
in PLWH were related to hypertension, diabetes (DM), and age.  
Conclusion: Further research needs to be done to determine why we have such a wide prevalence 
range. 
 
Keywords: chronic kidney disease; HIV; prevalence; systematic review 
 
Introduction 
Over one million Americans have human immunodeficiency virus (HIV) (CDC, 2017b). 
Since the development of combined antiretroviral therapy (cART), the life expectancy of persons 
with HIV has increased (Althoff et al., 2015; Joint United Nations Programme on HIV/AIDS, 
2013; Samji et al., 2013) such that they can expect to live about early 70 years, which is similar to 
the expected age of the general population (Nakagawa et al., 2012). With longer life spans, 
however, PLWH are developing other chronic medical conditions (Cailhol et al., 2011; Calza et 
al., 2014; Campbell et al., 2009; Winston, 2010). In the U.S., for example, it has been estimated 
that approximately 70% of PLWH have polymorbidity (Buchacz et al., 2013). This may be related 
to the negative side effects of cART, which include dyslipidemia (Buchacz et al., 2013; Cao et al., 
2013; Cheung et al., 2007; Fernando, Finkelstein, Moore, & Weissman, 2008), nephrotoxicity, and 
kidney stone formation (Izzedine, Harris, & Perazella, 2009).  
One of the most commonly diagnosed chronic diseases in PLWH is chronic kidney disease 
(CKD) (Naicker, Rahmanian, & Kopp, 2015). CKD is the irreversible destruction of the functional 
units of the kidney, or nephrons, which clean waste from the body and produce urine (Naftalin, 
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Nathan, Hamzah, & Post, 2011). If CKD is uncontrolled, irreversible damage to the kidneys will 
ultimately require dialysis (Gardner et al., 2003; Gupta et al., 2004). 
Many factors are associated with the development of CKD in PLWH, including 
hypertension, diabetes (DM), HIV treatments, African American race, and old age (Bonjoch et al., 
2014; Izzedine et al., 2009; Kopple, 2001; Naftalin et al., 2011; Naicker et al., 2015; Szczech et 
al., 2002; Winston, 2010). The relationship between hypertension and kidney disease has not yet 
been identified (Peck et al., 2014). The only known of currently, kidney disease is a secondary 
hypertension complication in PLWH (Peck et al., 2014). PLWH+DM tend to have more 
albuminuria than PLWH alone (48.0% vs. 33.3%, p < 0.05) in 2007 (Cohen et al., 2010), and 
albuminuria affects negative viral load (VL) suppression (Kim et al., 2011). HIV treatment, or 
cART, especially with tenofovir, affects the estimated glomerular filtration rate (eGFR) (Horberg 
et al., 2010) and can cause renal tubular dysfunction (Hall, Hendry, Nitsch, & Connolly, 2011). 
As CKD is a risk factor for end stage renal disease (ESRD) and death (Choi et al., 2010; Ibrahim 
et al., 2012), early identification of CKD can prevent or reduce the risk of complications such as 
kidney disease progression and cardiovascular events (Choi et al., 2010; Ibrahim et al., 2012). 
Current clinical guidelines suggest three- to six-month regular screenings using the eGFR (Asboe 
et al., 2012; Kopple, 2001; Winston, 2010).  
The purpose of this systematic review is to synthesize current research on CKD in PLWH. 
The specific aims are as follows: (1) to examine studies’ characteristics, (2) to explore eGFR used 
to define CKD, (3) to identify risk factors for CKD in PLWH, and (4) to investigate the prevalence 
of CKD in PLWH. 
Methods 
Search Strategy  
A systematic literature searches of studies from January, 2000 to August, 2016 was 
conducted in the PubMed and PsycInfo databases, using the following search terms: incidence, 
prevalence, diabetes, diabetes mellitus, renal failure, renal disease, chronic kidney disease, CKD, 
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kidney disease, HIV, AIDS, and human immunodeficiency virus. This search was supplemented by 
a manual search of relevant reference lists. Data extraction occurred as follows (see Figure 3). The 
initial database searches identified 1,960 citations in PubMed and 5,356 citations in PsycInfo, and 
the manual search of references found an additional 27. These citations were screened for 
duplicates, which were discarded, leaving 437. Titles and abstracts of the 437 articles were 
screened, and citations were excluded if articles were not written in English, not related to HIV-
infected people, or not related to those with CKD, and also if participants were not adults over 21 
years old; 61 articles then remained. These were then retrieved and reviewed in full; 21 articles 
from the database search were then excluded according to the following criteria: they did not 
address the prevalence of CKD in those with HIV; they were reviews, meta-analyses, or editorials; 
they presented acute kidney disease; or participants were pregnant women. In addition, 19 articles 
from the manual reference search were also excluded after applying the inclusion and exclusion 
criteria, leaving 21 studies for systematic review. Table 1 presents characteristics for CKD in 
PLWH in the reviewed studies. 
Results 
Study Characteristics 
The number of participants in the 21 reviewed articles ranged from 163 to 15,135 and 
represented diverse ethnicities or races (White, African American, Asian, etc.) and countries of 
origin. Seven articles (33.3%) were conducted in the U.S., and the remaining 14 studies (66.7%) 
were conducted in Asia, Africa, Europe, Israel, and Argentina. The total number of PLWH across 
the 21 studies was 43,215. Fourteen of the studies were cross-sectional (Ayokunle et al., 2015; 
Bonjoch et al., 2014; Burkhalter, Sannon, Mayr, Dickenmann, & Ernst, 2014; Cailhol et al., 2011; 
Calza et al., 2014; Campbell et al., 2009; Cao et al., 2013; Cheung et al., 2007; Fernando et al., 
2008; Hsieh et al., 2015; Okafor, Unuigbe, & Chukwuonye, 2016; Overton, Nurutdinova, 
Freeman, Seyfried, & Mondy, 2009; Sorlí et al., 2008; Wyatt et al., 2007), 6 were cohort studies 
(Berg et al., 2005; Choi et al., 2007a; Choi, Shlipak, Hunt, Martin, & Deeks, 2009; Lucas et al., 
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2008; Mocroft et al., 2007; Mocroft et al., 2010; Zachor et al., 2016), and 1 was a case study 
(Obirikorang, Osakunor, Ntaadu, & Adarkwa, 2014). We extracted the prevalence of CKD from 
all studies.  
Estimated Glomerular Filtration Rate (eGFR) in PLWH 
Several assessments were used to define CKD in PLWH. All of the articles used an eGFR 
of < 60 mL/min/1.73 m2. Equations for eGFR are used to index kidney function (Levey et al., 
2009). In the reviewed studies, three eGFR equation models were used to determine CKD in 
PLWH. Nineteen studies used the equation for modification of diet in renal disease (MDRD), 4 
studies used the CKD epidemiology collaboration (CKD-EPI) equation, and 4 studies used the 
Cockcroft-Gault creatinine clearance (CG) equation (see Table 2). Six studies used two equation 
models rather than one: three used MDRD and CKD-EPI (Bonjoch et al., 2014; Obirikorang et al., 
2014; Zachor et al., 2016), and three used MDRD and CG (Cailhol et al., 2011; Mocroft et al., 
2007; Sorlí et al., 2008).  
It is possible that a person would be classified as having CKD by one model but not by 
another. The CG equation is not recommended for clinical use because its non-standardized 
creatinine assays can overestimate kidney function (Stevens et al., 2009). Nowadays, the CKD-
EPI and the MDRD equations use standardized creatinine values because accurate creatinine level 
can determine kidney functions and will be used in determining drug doses, so we can prevent 
drug toxicity with accurate levels (Stevens et al., 2009). However, there is known systematic bias 
in the original MDRD model, owing that it was developed in a population of only persons with 
CKD. To reduce systematic bias of the MDRD, the CKD-EPI was developed using people without 
CKD which corrected for bias by increasing the variability (Levey & Stevens, 2010). 
Prevalence of CKD in PLWH  
Of the 43,215 PLWH across the 21 studies, 3,228 (7.5%) had CKD. The reported 
prevalence of CKD in PLWH ranged from 2.3% to 53.3%. The African American population had 
the highest prevalence (53.3%) (Okafor et al., 2016); the South African population had the lowest 
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(2.3%) (Zachor et al., 2016). In the U.S., the prevalence of CKD in PLWH ranged from 3.0% to 
23.7%. Table 1 presents the prevalence of CKD differentiated by population, study area, and study 
characteristics. Because the prevalence is highly varied, healthcare providers may need to take the 
characteristics of their population, including its location, into account when deciding whether or 
not to screen for CKD. Screening may need to be done more often depending upon the patient 
demographics. 
Risk factors for CKD in PLWH 
The risk factors for CKD in PLWH cited most often consisted of medication (total n = 13 
studies; tenofovir n = 6, indinavir n = 2, stavudine, nonsteroidal anti-inflammatory drugs 
[NSAIDS], aminoglycoside, drug toxicity, injection drug use n =1), hypertension (n = 12), older 
age (n = 9), DM (n = 8), hepatitis infection (n = 7), low level of CD4 cell count (n = 6), and race 
(n = 4) (see Table 3). Six studies cited tenofovir as a risk factor. Hepatitis C infection was cited 
more than the risk of hepatitis B (5 vs. 2 studies). Other risk factors were VL (n = 4), 
hyperlipidemias (n = 3), gender (n = 3), presence of proteinuria (n = 2), atherosclerosis (n = 1), 
and lipoatrophy (n = 1). Many risk factors, such as gender and race, are not mutable or may be 
caused by HIV or its treatment (glucose intolerance, lipodystrophy).   
Discussion  
The equation models used to eGFR differ, and each model has limitations. The MDRD 
equation was used most often to obtain eGFRs, but the MDRD cannot be used for people younger 
than 18 or older than 70 (National Institute of Diabetes and Digestive and Kidney Diseases, n.d.). 
This is important, because the average age of PLWH is increasing. Results differed depending on 
the equation used to obtain an eGFR (Van Pottelbergh et al., 2014). One study (Levey et al., 2009) 
indicated that the CKD-EPI equation is more accurate in diagnosing CKD than the MDRD 
equation, because the CKD-EPI has less bias and yields fewer median differences in eGFR than 
the MDRD, especially when eGFR is greater than 60mL/min/1.73m2. To determine the extent of 
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kidney damage and function and inform decisions about care, we need a standard equation model 
for eGFR that is appropriate for an aging population.  
The evidence from the 21 articles reviewed here indicates that there is an increased 
prevalence of CKD in PLWH as opposed to those without HIV. The broad 2.3% to 53.3% 
prevalence range for CKD in PLWH reflects differences in population size, region, race or 
ethnicity, and study characteristics. The study with the highest rate (53.3%) was conducted in 
South Nigeria, whose population consists of black people (Okafor et al., 2016) who have a genetic 
predisposition to CKD. African Americans with HIV have a higher chance of developing CKD 
than those of other ethnicities (Wyatt et al., 2007). As stated above, providers should consider the 
population when making decisions to screen for CKD.  
The most severe risk factor for CKD in PLWH was medication, especially given the 
extensive use of tenofovir (Labarga et al., 2009). Using tenofovir causes nephrotoxicity (Fux, 
Christen, Zgraggen, Mohaupt, & Furrer, 2007), renal injury, proximal renal tubulopathy, and 
reduced eGFR (Cooper et al., 2010; Horberg et al., 2010). Therefore, medical providers need to be 
especially diligent in monitoring kidney damage once a patient has been placed on combined 
antiretroviral therapy. 
Conclusion 
CKD is one of the most significant comorbid conditions for PLWH. The mortality rates for 
CKD in PLWH is higher than in those without HIV(Choi et al., 2007b). The range for the 
prevalence of CKD in PLWH is wide. Uniform use of the CKD-EPI as the assessment for CKD 
would increase the accuracy of CKD diagnosis.  
Strengths and Limitations  
This systematic review of the existing studies regarding the prevalence of CKD in PLWH 
is comprehensive, but the varying prevalence of CKD in the studies may limit the generalizability 
of the review’s findings.   
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Figure 3. Search Flow chart using the PRISMA guideline (http://prisma.thetacollaborative.ca) 
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Table 1. Chronic Kidney Disease (CKD) in HIV-infected individual characteristics. 
Study 
 
Origin n* CKD criteria CKD 
prevalence 
in PLWH  
N (%) 
CKD risk factors in 
PLWH 
Research 
Design 
Biomarker 
Ayokunle et al. 
(2015)  
Nigeria 227  eGFR	≤	60ml/min/1.73m2, 
and/or ACR	≥	30mg/g 108  (47.6) Low CD4 Cross-sectional MDRD 
Bonjoch et al. 
(2014) 
US 970  eGFR < 60ml/min/1.73m2 
UPC or UAC ratio  
29  
(3) 
HTN, Age, Tenofovir Cross-
sectional 
MDRD 
CKD-EPI 
 
Burkhalter et al. 
(2014) 
Haiti 164 eGFR < 90ml/min/1.73m2, 
and/or proteinuria by 
dipstick test 
5  
(3.1) 
None Cross-
sectional 
CKD-EPI 
Cailhol et al. 
(2011)  
Burundi 300  eGFR < 60ml/min/1.73m2, 
and/or kidney damage 
defined as a urinary 
abnormality at any eGFR 
level 
137  
(45.7) 
DM, HTN, HBV, 
HCV, Aminoglycoside 
NSAIDS  
Cross-
sectional 
MDRD 
Cockcroft-
Gault 
Calza et al. 
(2014)  
Italy 894 eGFR < 90ml/min/1.73m2, 
and/or renal damage or 
eGFR < 60ml/min/1.73m2≥ 
3 months 
 
190  
(21.3) 
Age, Male, HTN, DM, 
Proteinuria, 
Hyperlipidemias 
(Hypertriglyceridemia), 
Low CD4, Tenofovir, 
AA 
Cross-
sectional 
MDRD 
Campbell et al. 
(2009)  
UK 3,439  eGFR < 
60ml/min/1.73m2	≥	3 
months, the severity of 
CKD categorized as stage 
3-5 
81  
(2.4) 
DM, HTN, 
Atherosclerosis,  
Drug toxicity  
Cross-
sectional 
MDRD 
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Table 1. Continued 
Study 
 
Origin n* CKD criteria CKD 
prevalence 
in PLWH  
N (%) 
CKD risk factors in 
PLWH 
Research 
Design 
Biomarker 
Cao et al. (2013)  China 538  eGFR < 60ml/min/1.73m2,    
and/or isolated proteinuria ≥	1+ on urine epipstick ≥	3 months 
86  
(16) 
Age, HTN, HCV, VL  Cross-
sectional 
MDRD 
Cheung et al. 
(2007)  
China 322 eGFR < 60ml/min/1.73m2 
or Proteinuria more than 3 
months (PR/CR > 0.3g/g) 
54  
(16.8) 
Age, HTN, DM, 
Indinavir, Low CD4, 
VL 
Cross-
sectional 
MDRD 
Choi et al. 
(2007b) 
US 15,135 eGFR	≤	60ml/min/1.73m2 1,075 
(7.1) 
Age, HTN, HCV, VL Cohort MDRD 
Choi et al. 
(2009) 
US 615 eGFR < 60ml/min/1.73m2 
 
45 (7.8) Female, DM, 
Hyperlipidemia 
Cohort MDRD 
Fernando et al. 
(2008)  
US 422  eGFR < 60ml/min/1.73m2 100  
(23.7) 
HTN, DM, AA Cross-
sectional 
MDRD 
Hsieh et al. 
(2013) 
Taiwan 512  ACR≥	30mg/g and/or a 
protein≥	1+ on urine 
examination, and/or eGFR 
< 60ml/min/1.73m2	 ≥	3months 
36  
(7.03) 
DM, HTN, 
Hyperlipidemias 
(Hypercholesterolemia) 
Cross-
sectional 
MDRD 
Lucas et al. 
(2008) 
US 4,227  eGFR < 60ml/min/1.73m2 ≥	3 months 
 
284  
(6.7) 
  
DM, HTN, HBV, 
Injection drug use, 
HCV, AA 
Cohort MDRD 
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Table 1. Continued 
Study 
 
Origin n* CKD criteria CKD 
prevalence 
in PLWH  
N (%) 
CKD risk factors in 
PLWH 
Research 
Design 
Biomarker 
Mocroft et al. 
(2010) 
EuroSIDA 6,843  eGFR < 60ml/min/1.73m2 281 (4.1) Tenofovir Cohort Cockcroft-
Gault 
Mocroft et al. 
(2007) 
EuroSIDA 4,474  eGFR < 60ml/min/1.73 m2 157 (3.5) Age, Low CD4, 
Indinavir, Tenofovir  
Cohort Cockcroft-
Gault 
MDRD 
Obirikorang et 
al. (2014)  
Ghana 163  eGFR < 60ml/min/1.73m2 
 
16 (9.9) None Case 
control 
MDRD 
CKD-EPI 
 
Okafor et al. 
(2016)  
South 
Nigeria 
382  eGFR < 60ml/min/1.73 m2 
ACR	≥	200mg/g 204 (53.3) None Cross-sectional MDRD 
Overton et al. 
(2009)  
US 845  eGFR < 60ml/min/1.73 m2 
 
68 (8) Low CD4, HTN, 
proteinuria, Tenofovir, 
Stavudine, VL 
Cross-
sectional 
MDRD 
Sorlí et al. 
(2008)  
Spain 854  eGFR < 60ml/min/1.73 m2 65 (7.6) Age, Female, 
Lipoatrophy 
Cross-
sectional 
Cockcroft-
Gault 
MDRD 
Wyatt et al. 
(2007)  
US 1,239  eGFR < 60ml/min/1.73 m2,  
and/or proteinuria 
>100mg/dl 
192 (15.5) 
 
Age, AA, HCV, Low 
CD4 
Cross-
sectional 
MDRD 
Zachor et al. 
(2016)  
South 
Africa 
650  eGFR < 60ml/min/1.73 m2 
 
15 (2.3) HTN, Age, Tenofovir Cohort CKD-EPI 
MDRD 
*: Number of participants who have HIV 
Notes. AA, African American; ACR, albumin creatinine ratio; CKD-EPI, chronic kidney disease epidemiology collaboration equation; 
DM, diabetes; eGFR, (estimated) glomerular filtration rate; HTN, hypertension; MDRD, modification of diet in renal disease 
equation; UAC, urinary albumin: creatinine; UPC, urinary protein: creatinine; VL, viral load  
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Table 2. eGFR Equations 
Biomarker Equation‡ CKD criteria 
MDRD  
(Ayokunle et al., 2015; Bonjoch et al., 
2014; Cailhol et al., 2011; Calza et al., 
2014; Campbell et al., 2009; Cao et al., 
2013; Cheung et al., 2007; Choi et al., 
2007b, 2009; Fernando et al., 2008; 
Hsieh et al., 2013; Lucas et al., 2008; 
Mocroft et al., 2007; Obirikorang et al., 
2014; Okafor et al., 2016; Overton et al., 
2009; Sorlí et al., 2008; Wyatt et al., 
2007; Zachor et al., 2016) 
eGFR (mL/min/1.73 m2) = 175 × (Scr)-1.154 
× (Age)-0.203 × (0.742 if female) × (1.212 if 
African American) 
eGFR < 60 mL/min/1.73 m2 
The equation has not been validated 
in patients older than 70. 
CKD-EPI  
(Bonjoch et al., 2014; Burkhalter et al., 
2014; Obirikorang et al., 2014; Zachor et 
al., 2016) 
eGFR = 141 × min (Scr/κ, 1)α × max(Scr/κ, 
1)-1.209 × 0.993Age × 1.018 [if female] × 
1.159 [if African American] 
This equation provides a more 
accurate estimation than the MDRD. 
 
Cockcroft-Gault  
(Cailhol et al., 2011; Lucas et al., 2008; 
Mocroft et al., 2007; Sorlí et al., 2008) 
Men = (140 - age) x ideal weight 
0.814 x [serum creatinine] 
    
Women = 0.85 x creatinine clearance in men 
Used in clinical practice to guide 
dose reductions of renal excreted 
drugs. 
 
*: References cited may duplicate studies. 
‡: This equation comes from Levey et al. (2009): Scr. serum creatinine in mg/dL; κ .0.7 for females and 0.9 for males; α. -0.329 for 
females and -0.411 for males; min. the minimum of Scr /κ or 1; max. the maximum of Scr /κ or 1. 
Notes. CKD-EPI, chronic kidney disease epidemiology collaboration equation; eGFR, (estimated) glomerular filtration rate; MDRD, 
modification of diet in renal disease equation. 
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Table 3. Risk Factors for CKD in PLWH 
CKD risk factors in PLWH n* CKD risk factors in PLWH n* 
Hypertension 12 Medication – Stavudine 1 
Diabetes 8 Medication – NSAIDS 1 
Race: African American 4 Medication – Aminoglycoside 1 
Hyperlipidemias 3 Medication – Drug toxicity 1 
Older age 9 Medication – Injection drug use 1 
Low CD4 cell count 6 Atherosclerosis 1 
Gender – Male  1 Viral load 4 
Gender – Female 2 HBV 2 
Presence of proteinuria 2 HCV 5 
Medication – Tenofovir  6 Lipoatrophy 1 
Medication – Indinavir 2 Not indicated  3 
 
*: References cited may duplicate studies.  
Notes. HBV, hepatitis-B virus; HCV, hepatitis-C virus; NSAIDS, nonsteroidal anti-inflammatory 
drugs. 
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SURVIVAL RATES IN PLWH 
Due to the development of cART, survival rates of PLWH are longer than before (Alter, 
2006; Poorolajal, Hooshmand, Mahjub, Esmailnasab, & Jenabi, 2016). In addition, cART has 
reduced the number of HIV- and AIDS-related deaths by 2.5 million in low- and middle-income 
countries since 1995 (Venegas et al., 2008), and it has increased the number of survival years from 
10–12 years to 25 years in PLWH (Alencar, Duarte, & Waldman, 2014; Kee et al., 2009). cART 
makes PLWH increase their CD4 cell count (Mills et al., 2008) and strengthens their immune 
systems (Poorolajal et al., 2016), which prevents the disease’s progression (Mills et al., 2008). 
However, since HIV infection was defined, approximately 75 million people have gotten HIV 
infection and about 36 million people have died from issues related to HIV infection (Poorolajal 
et al., 2016).   
One study (N = 585) from Iran figured out the survival rates divided into one-year, five-
year, and ten-year categories (Mirzaei, Poorolajal, Khazaei, & Saatchi, 2013). The one-year 
survival rate was 87%, five-year survival rate was 67%, and ten-year survival rate was 40% 
(Mirzaei et al., 2013). Also, the HR between mortality related to AIDS causes was 4.77 (p < 0.001) 
among those who did not receive cART (Mirzaei et al., 2013). The other study, the meta-analysis 
study (N = 27,862) pointed out that in those who received cART, the survival rates at 2, 4, 6, 8, 
and 10 years were 87%, 86%, 78%, 78%, and 61%, respectively, while in those who did not receive 
cART, the survival rates at 2, 4, and 6 years were 48%, 26%, and 18%.    
To conclude, those previous studies pointed out that PLWH who receive cART have higher 
survival rates than PLWH who do not receive cART. It is thus important to receive cART in PLWH 
to increase the survival rates. The other study also pointed out that due to development of cART, 
PLWH are getting older and have a higher chance of developing chronic diseases, which then 
cause an increase in non-HIV-related mortality rates (Braithwaite et al., 2005; Weber et al., 2013). 
As such, it is important to take care about mortality rates in PLWH with comorbid conditions. 
However, there are no studies on survival rates of PLWH with comorbid conditions. Therefore, 
we need more research on survival rates in PLWH with comorbid conditions. 
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SUMMARY 
Research on retention in care in OALWH+DM is significantly important because previous 
studies have emphasized that the OALWH population is increasing significantly, and they have 
more of a chance to develop comorbid conditions such as DM and CKD. Retention in care is 
closely related with health outcomes in PLWH. However, as of the current study, there is no gold 
standard method of measuring retention in care in OALWH+DM, so this study will serve as a 
guideline of retention in care in OALWH+DM. In addition, the common complication of 
PLWH+DM is CKD and CKD is highly correlated with mortality rates. But no studies have 
considered both DM and CKD in PLWH, so this dissertation will serve as a guideline of CKD 
occurrence and mortality rate in PLWH with comorbid conditions in the future. 
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Chapter Three: Retention in Care and Symptom Burden in Persons living 
with HIV with Diabetes for Adults over 50 
ABSTRACT 
Background: Many people in the United States suffer with a human immunodeficiency virus (HIV) 
infection. Diabetes (DM) is the second most common comorbid condition among persons living 
with HIV (PLWH). The key to successful HIV management is retention in care. The purpose of 
this study is to investigate the relationships of retention in care measurements in PLWH+DM by 
age groups and relationships between symptom burden and retention in care PLWH+DM by age 
groups.   
Methods: This is a secondary data analysis from the Center for AIDS Research (CFAR) Network 
of Integrate Clinic Systems (CNICS), which includes in more than 32,000 PLWH. We measured 
the retention in care in PLWH+DM during calendar year 2015 who visited CNICS clinic at least 
once. Six retention in care measurements for PLWH+DM were defined: missed visits (count, 
dichotomous); visit adherence; 6-month gap; 4-month visit constancy; and the Health and 
Resources Services Administration HIV/AIDS Bureau (HRSA HAB) measure retention in care 
measurement. We conducted Spearman correlation coefficients and logistic regression to 
investigate measurements in PLWH+DM, as well as multi-group path analysis for comparing 
retention in care in PLWH+DM. For investigating relationships between symptom burden (HIV 
Symptom Index) and retention in care, we conducted logistic regression for PLWH+DM by age 
groups. 
Results: A total of 798 samples have PLWH+DM in calendar year 2015. Those older adults (OA) 
PLWH+DM had 564 samples and younger adults (YA) PLWH+DM had 234 samples. Most of the 
retention in care in PLWH+DM measurements were significantly correlated (p < 0.05). Only 4-
month visit constancy was not correlated. Except missed visits (count) in OALWH+DM, no 
significant relationship exists between retention in care measurements CD4 cell count using 
logistic regression. But multi-group path analysis demonstrated that CD4 cell count had significant 
relationships with most retention in care measurements in all age groups. Still, hemoglobin A1c 
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(HbA1c) level was the only significant relationship with most of retention in care measurements 
in YALWH+DM. As for symptom burden, significant relationships took place with symptom 
burden (fatigue, sadness, memory loss) and retention in care in OALWH+DM. 
Conclusion: The results showed that retention in care have relationships with disease control (CD4 
cell count, and HbA1c level) in PLWH+DM, and notably, HbA1c level was only significantly 
affected by YALWH+DM. In future research, we need to find more accurate reasons why the 
HbA1c level only significantly relationships with YALWH+DM. This study can contribute to 
guide research on PLWH+DM in the future. 
 
Keywords: CD4 cell count, diabetes, Hemoglobin A1c, HIV, retention in care 
 
INTRODUCTION 
Overall, 1.2 million people in the United States are suffering from an HIV (CDC, 2017b). 
Due to the development of the combined antiretroviral therapy (cART), the life expectancy of 
persons living with human immunodeficiency virus (HIV) (PLWH) has extended to the early 70s, 
which comparable to the general population’s life expectancy (Antiretroviral Therapy Cohort 
Collaboration, 2008; Samji et al., 2013). As PLWH aging, however, more than half have at least 
one comorbid condition (Rolls et al., 2014). Diabetes (DM) is one of the most common comorbid 
conditions (Brown et al., 2005; Butt et al., 2009; Medapalli et al., 2012) among PLWH over 50 
years old (Vance et al., 2011) and 10 to 15% of PLWH have DM (Brown et al., 2010; Butt et al., 
2009). A recent study indicated that PLWH have higher chance of developing DM than their 
seronegative counterparts (Brown et al., 2010; Butt et al., 2009; De Wit et al., 2008). One of the 
most common reasons for PLWH developing DM is due to the combined antiretroviral therapy’s 
(cART) adverse effects (Brown et al., 2005; De Wit et al., 2008; Kim et al., 2011; Ledergerber et 
al., 2007). The cART promotes the glucose intolerance (Brown et al., 2005; De Wit et al., 2008; 
Kim et al., 2011; Ledergerber et al., 2007). One of the cART, HIV-1 protease inhibitors (PIs), 
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increases insulin resistance (Cheng et al., 2004) and interrupts insulin secretion (Dagogo-Jack, 
2008), which increases blood glucose levels. 
Moreover, having chronic diseases increases symptom burden (Harding, Molloy, 
Easterbrook, Frame, & Higginson, 2006; Zuniga, Nguyen, & Holstad, 2016) such as loss of energy, 
mental drowsiness, sleeping problems, and pain (Lee et al., 2009). Symptom burden is defined as 
“the observations of the patient, the person experiencing the evidence of disease or physical 
disturbance” (Cleeland, 2007, p.17). The World Health Organization (WHO) advocates that 
healthcare professionals need to control symptoms in PLWH (World Health Organization, n.d.) 
because having symptom burdens relates to the poor health outcomes such as poor medicine 
adherence, decreased patient quality of life, as well as progression of the HIV disease (Gay et al., 
2011; Gonzalez et al., 2007; Harding et al., 2012; Holzemer et al., 2001; World Health 
Organization, n.d.). Thus, it is important to take care about symptom burden care in PLWH+DM.   
 Due to prolonged life in PLWH, the portion of older adults (OA) in PLWH is growing 
sharply (Effros et al., 2008), accounting for 17% of PLWH in 2014 (CDC, 2017c). Followed by 
the previous studies, older adults living with HIV (OALWH) are considered over 50 years old in 
PLWH (Emlet, 2006; Legarth et al., 2016; Savasta, 2004; Webel et al., 2014). PLWH over the age 
of 50 have unique barriers to managing their conditions such as age-related comorbid conditions 
(Emlet & Farkas, 2002). Approximately 30% of OALWH had at least two chronic conditions 
(Negin et al., 2012). Despite this, there is a lack of studies considering comorbid conditions in 
OALWH population. Long-term control of both diseases is a key to survival and better quality of 
use. Many studies demonstrated that retention in care is the most important to HIV management 
success (Geng et al., 2010) because retention in care enables PLWH to undergo cART, manage of 
medication toxicity, and prevent HIV treatment failure (Geng et al., 2010). Through this process, 
we can slow or halt development of disease progression that commonly results in acquired immune 
deficiency syndrome (AIDS), which is the last stage of HIV (AIDS Info, 2016e). After entering 
the AIDS stage, mortality rates steeply increase, thereby creating the need to prevent HIV 
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infections to develop into AIDS, and key to this success is retention in care. Even so, no study thus 
far has explained the standard measurements of retention in care who have DM with PLWH.  
The purpose of this study is to investigate the relationships of retention in care 
measurements in PLWH+DM by age groups and relationship between symptom burden and 
retention in care in in PLWH+DM by age groups.   
METHODS 
Research Design 
This study involved a secondary data analysis of the Center for AIDS Research (CFAR) 
Network of Integrate Clinic Systems (CNICS) database, which includes medical records for 
PLWH since 1995. This study is a longitudinal retrospective cross-sectional study based on the 
study by Mugavero, Westfall, et al. (2012), which set the ‘gold standard’ of measurements in 
PLWH regardless of comorbid conditions. 
Study Setting and Sample  
This study involved accessing the CNICS database and collecting data from eight clinical 
sites: The University of Washington; Case Western Reserve University; The University of 
California, San Francisco; The University of North Carolina at Chapel Hill; Johns Hopkins 
University; Fenway Health in Boston; The University of California, San Diego; and The 
University of Alabama at Birmingham. The CNICS data captured a wide range of information in 
more than 798 PLWH+DM who were older than 18 years in calendar yeanr2015, and all of the 
participants were receiving cART from the CNICS clinic sites for at least six months. The CNICS 
includes demographics (age, gender, race/ethnicity), biomarkers (CD4 cell count, hemoglobin A1c 
[HbA1c] level), and CNICS clinic visits records. This study used the DM (HbA1c > 6.5 % and/or 
have DM medications) demographic from the CNICS as a criterion. Health care utilization data 
consisted of visits and appointment status. This study was considered exempt from the University 
of Texas at Austin Institutional Review Board because the data from the Center for AIDS Research 
(CFAR) Network of Integrated Clinic Systems (CNICS) were already de-identified. 
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Inclusion/Exclusion Criteria 
To be considered for inclusion for the study, PLWH+DM samples must have a diagnosis 
of DM verified by HbA1c > 6.5 % or have DM medications, and have had at least one primary 
HIV-care appointment at a CNICS clinic site during the 2015 calendar year. This study considered 
retention in care in only the 2015 calendar year. 
Sample Size 
To determine the power of our research, the researchers presented the results of the power 
analyses to justify the sample size using G-Power 3.1.9.2 for Mac (Faul, Erdfelder, Buchner, & 
Lang, 2009; Faul, Erdfelder, Lang, & Buchner, 2007). In the power analysis for the Spearman’s 
correlation coefficient for power, the total sample size needed is 23 people at an alpha of 0.05, a 
power of 0.80, and a medium effect size (ρ = 0.5) (Cohen, 1992). Seeing this, the sample size for 
the current study is sufficient to meet the power requirements. The total sample was 798 
PLWH+DM.  
Measures of Retention in Care in PLWH+DM 
Demographic Measures 
Demographic measures included age (dichotomous, 0: > 50 years old, 1: ≤ 50 years old), 
present gender, race/ethnicity, and CD4 cell count (categorical, 0: ≥ 500 cells/µL, 1: 200–499 
cells/µL, 2: < 200 cells/µL). For DM diagnosis, we used HbA1c level over > 6.5% and/or having 
DM medications, which the CNICS defined. 
Measures of Retention in Care in PLWH+DM  
The measures of retention in care in PLWH+DM were number of missed clinic visits, 
number of clinic visits attendance (attendance), visit adherence, and visit consistency during the 
one-year period (2015). Missed visits included no-show visits that were not cancelled or bumped 
by clinic staff, which refers to people missing clinic appointments without any notice. Missed visits 
were coded using a count and dichotomous measure (0: visits vs. 1: no-show visits). Attendance 
was shown as the total counts of participants who actually visited clinics during the 2015 calendar 
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year (continuous). Visit adherence was calculated as a proportion of appointments kept compared 
to appointments scheduled (continuous, range: 0–100%). Visit constancy was measured three 
ways: 4-month visiting constancy, 6-month visiting gap, and the U.S. Health Resources and 
Services Administration HIV/AIDS Bureau (HRSA HAB) measure outcomes. The 4-month 
visiting constancy considered the number of patients who had kept visits (categorical, range: 0–3), 
and the 6-month visiting gap assessed whether patients made visits at least once in no less than 
189 days using a dichotomous measure (0: not retained, 1: retained). The HRSA HAB measure 
determined whether patients made their visits at least 90 days apart using a dichotomous measure 
during 2015 (0: not retained, 1: retained 90-day gap).  
Outcome Variables  
There were two outcome variables to measuring retention in care in PLWH+DM: HIV 
disease control and DM disease control. HIV disease control was measured by CD4 cell count at 
the last visit. DM disease control was assessed through most recent HbA1c level. A CD4 cell count 
under 200 cells/µL is considered the last stage of HIV infection, commonly called AIDS and 
common people have CD4 cell count no more than 500 cells/µL, which indicates sustained good 
health status of HIV treatments (AIDS Info, 2016b). The HbA1c level reflects three-month 
glycemic control (Nasir et al., 2010), which signifies DM management to physician and patients 
(Cagliero, Levina, & Nathan, 1999). Usually, the DM control in PLWH used a HbA1c less than 
6.5% (Eckhardt et al., 2012; Tien et al., 2012). 
To investigate symptom burden and retention in care in PLWH+DM, we used the HIV 
Symptom Index (Justice et al., 2001), which consists of 20 items, namely fatigue, fever, dizzy, 
neuropathy, memory loss, nausea, diarrhea, sadness, anxious, sleep problems, skin problems, 
coughing, headache, loss appetite, bloating, muscle aches, sex problems, body fat, weight loss, and 
hair loss. The HIV Symptom Index has 5 response choices—0: I do not have the symptom; 1: I 
have the symptom, but it does not bother me; 2: I have the symptom, but it bothers me little; 3: I 
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have the symptom, and it bothers me some; or 4: I have the symptom, and it bothers me a lot 
(Justice et al., 2001).  
Statistical Analyses 
Descriptive statistical analyses included demographic characteristics (age, present gender, 
race/ethnicity, missed visit [count, dichotomous], attendance, visit adherence, 4-month visit 
constancy, 6-month gap, HRSA HAB measure, HbA1c level, CD4 cell count) using means, 
standard deviation (SD), range of scores, frequencies, and percentages. 
Spearman’s correlation coefficients were used to evaluate the associations among retention 
in care measurements and health outcomes (CD4 cell count, HbA1c level). Spearman’s correlation 
coefficients were used to test the associations among retention in care measurements (missed visit 
[count, dichotomous], visit adherence, 4-month visit constancy, 6-month gap, HRSA HAB 
measure) by age groups. Logistic regression investigated association between retention in care 
measurements (missed visit [count, dichotomous], visit adherence, 4-month visit constancy, 6-
month gap, HRSA HAB measure), and HIV infection health status determined by a CD4 cell count 
of no more than 500 cells/µL by two age groups. 
To investigate the association between the symptom burden in PLWH+DM using the HIV 
symptom index by different age groups and retention in care, researchers conducted logistic 
regression. To investigate association between retention in care and symptom burden, we used the 
HRSA HAB measure which was dichotomous variables (0: not retained; 1: retained 90-days gap). 
To investigate the relationships between retention in care measurements and disease control (CD4 
cell count, HbA1c level) in PLWH+DM by age groups, the researchers conducted multi-group 
path analysis. For path analysis, we considered missed visits (count), visit attendance (count, actual 
visit clinic times), visit adherence, and 4-month visit constancy for retention in care in PLWH+DM 
as independent variables and CD4 cell count and HbA1c level as dependent variables. The chi-
square statistic, the normed fit index (NFI), the Tucker-Lewis Index (TLI), the comparative fit 
index (CFI), and root mean square error of approximation (RMSEA) were used to estimate model 
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fit. All significant statistic levels are within p < 0.05. All statistical analyses were conducted using 
SPSS version 23.0 for PC (IBM Corp, Released 2015) and AMOS version 23.0 for PC (Arbuckle, 
2014).  
RESULTS 
Descriptive Statistics  
Study Characteristics in PLWH+DM in All Age Groups 
The total number of PLWH+DM in this study was 798. Descriptive statistics are presented 
in the respective sections on Table 4. The mean age of participants was 55.01years ± 8.961, 77.4% 
were male, and the most-often reported race or ethnicity was PLWH White-Non-Hispanic (41.1%) 
followed quite closely by African American-Non-Hispanic (40.3%). PLWH+DM had a mean 
HbA1c level of 7.565 ± 1.93 (n = 179), and 64.2% had a HbA1c level over 6.5%. Also, 32% had 
a CD4 cell count of less than 500 cells/µL, and 6.7% of them had less than 200 cells/µL, which is 
classified as AIDS which is the last stage of HIV. PLWH+DM missed visits (count) mean was 
0.29 ± 0.90 during the 12-month period in 2015, and among them, 16.3% had at least more than 
one missed visit. Their attendance range was 0–26 in 2015, and the mean was 3.07 ± 2.517. Mean 
of visit adherence was 0.904 ± 0.24, and 5.9% of PLWH+DM visit adherence occurred less than 
50% of the time. Among 772, only 29% attended all of their 4-month constancy visits, among 606, 
5.9% had a 6-month or greater gap, and 31% were not retained in the HRSA HAB measure 
(n = 606).  
Study Characteristics in OALWH +DM and YALWH+DM 
The sample of OALWH+DM was 564 with a mean age of 59.35 years ± 7.22, and 
YALWH+DM numbered 234, with a mean 44.56 years ± 5.10 (see Table 4). The two groups 
were statistically similar in missed visits (count, dichotomous), visit adherence, 4-month visit 
constancy, 6-month gap, CD4 cell count, and HbA1c level (p > 0.05). However, there were 
significant differences between the two groups in gender, race/ethnicity, and attendance (p < 
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0.05). Both OALWH+DM and younger adults living with HIV (YALWH) with DM mostly 
consisted of male participants (80%, and 71.4%, respectively; p = 0.01). The most common 
race/ethnicity were white–Non-Hispanic in OALWH+DM (45.2%) and African American–Non-
Hispanic in YALWH+DM (45.3%) (p = 0.001). The attendance range was 0 to 26 in both 
groups, and there were significant mean differences in attendance (OALWH+DM; 3.05 ± 2.417, 
YALWH+DM: 3.12 ± 2.747). The mean of visit attendance in OALWH+DM was 3.05 ± 2.417 
and 3.12 ± 2.747 in YALWH+DM (p = 0.01).   
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Table 4. Study characteristics in PLWH+DM 
Characteristics  
All age groups PLWH+DM  
(N = 798)‡ 
OALWH+DM  
(N = 564)‡ 
YALWH+DM 
(N=234)‡ 
Pearson Chi-Square 
or Fisher Exact‡‡  
Age (years) Mean ± SD 55.01 ± 8.96 59.35 ± 7.22 44.56 ± 5.10  
OALWH+DM 564 (70.7%)    
YALWH+DM 234 (29.3%)    
Gender     0.01** 
Male 618 (77.4%) 451 (80%) 167 (71.4%) 
Female 180 (22.6%) 113 (20%) 67 (28.6%) 
Race/Ethnicity   n = 794 n = 560  0.001*** 
White—Non-Hispanic 326 (41.1%) 253 (45.2%) 73 (31.2%) 
White—Hispanic 98 (12.3%) 62 (11.1%) 36 (15.4%) 
African American—Non-Hispanic 320 (40.3%) 214 (38.2%) 106 (45.3%) 
African American—Hispanic 3 (0.4%) 0 (0%) 3 (1.3%) 
Hispanic 18 (2.3%) 12 (2.1%) 6 (2.6%) 
Others 29 (3.7%) 19 (3.4%) 10 (4.3%)  
Missed visits (count) 
Mean ± SD  
Range: 0–12 
0.29 ± 0.90 
Range: 0–5 
0.24 ± 0.66 
Range: 0–12 
0.41 ± 1.30 
0.23 
Zero 667 (83.6%) 476 (84.4%) 191 (81.6%) 
One 84 (10.5%) 61 (10.8%) 23 (9.8%) 
Two 27 (3.4%) 16 (2.8%) 11 (4.7%) ≥	Three 20 (2.4%) 11 (2%) 9 (3.7%) 
Missed visits (Dichotomous)     0.35 
No missed visits 667 (83.6%) 476 (84.4%) 191 (81.6%) 
Have at least one missed visits 1 (16.4%) 88 (15.6%) 43 (18.4%) 
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Table 4. Continued  
Characteristics 
All age groups PLWH+DM  
(N = 798)‡ 
OALWH+DM  
(N = 564)‡ 
YALWH+DM 
(N=234)‡ 
Pearson Chi-Square 
or Fisher Exact‡‡  
Attendance 
Mean ± SD  Range: 0–26 3.07 ± 2.517 
Range: 0–26 
3.05 ± 2.417 
Range: 0–26 
3.12 ± 2.747 
0.01** 
Visit adherence    0.06 
Mean ± SD 0.904 ± 0.24 0.910 ± 0.23 0.890 ± 0.25 
0 – 24% 33 (4.1%) 23 (4.1%) 10 (4.3%) 
25 – 49% 15 (1.8%) 12 (2.1%) 3 (1.3%) 
50 – 74% 62 (7.9%) 34 (6%) 28 (11.6%) 
75 – 99% 47 (5.9%) 37 (6.6%) 10 (4.2%) 
100% 641 (80.3%) 458 (81.2%) 183 (78.2%) 
4-month visit constancy (Intervals 
with	≥	1 kept visit)  n = 772 n = 546 n = 226 0.67 
Zero 7 (0.9%) 5 (0.9%) 2 (0.9%) 
One 207 (26.8%) 143 (26.2%) 64 (28.3%) 
Two 334 (43.3%) 244 (44.7%) 90 (39.8%) 
Three 224 (29%) 154 (28.2%) 70 (31%) 
6-month gap  
(≥189 days between sequential kept visits)  n = 606 n = 425 n = 181 0.19 
No (retained) 570 (94.1%) 396 (93.2%) 174 (96.1%) 
Yes (not retained) 36 (5.9%) 29 (6.8%) 7 (3.9%) 
HRSA HAB measure  
(2 kept visits > 90 days apart)  
n = 606 n = 425 n = 181 0.39 
Retained 418 (69%) 298 (70.1%) 120 (66.3%) 
Not retained 188 (31%) 127 (29.9%) 61 (33.7%) 
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Table 4. Continued 
Characteristics  
All age groups PLWH+DM  
(N = 798)‡ 
OALWH+DM  
(N = 564)‡ 
YALWH+DM 
(N=234)‡ 
Pearson Chi-Square 
or Fisher Exact‡‡  
HbA1c 
Mean ± SD  
n = 179 
7.565 ± 1.93 
n = 179 
7.529 ± 1.90 
n = 179 
7.69 ± 2.03 
0.07 ≤	6.5% 64 (35.8%) 50 (36%) 14 (35%) 
> 6.5% 115 (64.2%) 89 (64%) 26 (65%) 
CD4 cell count 
Mean ± SD  
n = 194 
717.84 ± 407.42 
n = 151 
696.44 ± 387.06 
n = 43 
792.98 ± 469.35 
0.61 ≤	500 cells/µL 132 (68%) 102 (67.5%) 30 (69.8%) 
200 – 499 cells/µL 49 (25.3%) 40 (26.5%) 9 (20.9%) 
< 200 cells/µL 13 (6.7%) 9 (6%) 4 (9.3%) 
 
‡: Indicates the total sample size of the groups, but some variables have different sample sizes as presented on each table. 
‡‡: Pearson Chi-Square or Fisher Exact between OALWH+DM, and YALWH+DM 
*: Significant level p < 0.05 
**: Significant level p < 0.01 
*** : Significant level p < 0.001
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Retention in Care Measurements 
PLWH+DM in All Age Groups 
To compare the six measurements of retention in care in PLWH+DM, we conducted the 
Spearman’s correlation coefficients at the significance level p < 0.05 (see Table 5). Missed visits 
(dichotomous) correlated as highly positively with missed visits (count) measurement (0.996) at 
the significance level of p < 0.01. Visit adherence had a high negative correlation with missed 
visits measurements (count/dichotomous) (–0.854, p < 0.01). Despite these findings, 4-month visit 
constancy and 6-month gap demonstrated that no significant correlation existed between missed 
visits (count, dichotomous) and visit adherence (p < 0.05), and only 4-month visit constancy and 
6-month gap had a low negative correlation between them (–0.105, p < 0.01). The HRSA HAB 
measure had lower positive correlations with visit adherence (0.130, p < 0.01), and 6-month gap 
(0.169, p < 0.01). Moreover, the other measurement (missed visits [count, dichotomous] had a 
negative correlation with the HRSA HAB measure (–0.141, –0.140, respectively, p < 0.01). On 
the contrary, the HRSA HAB measure had a high positive correlation with 4-month visit constancy 
(0.93, p < 0.05).  
OALWH+DM  
By comparison, when we conducted the Spearman’s correlation coefficients for all six 
retention in care measurements for OA resulted in a different correlation pattern, with fewer 
significant correlations (See Table 6). Missed visits (count) and (dichotomous) variables correlated 
highly positively (0.997, p < 0.01), and those variables had a high negative correlation with visit 
adherence (–0.854, –0.855, respectively, p < 0.01). However, 4-month visit constancy and 6-
month gap measurements did not have significant correlations with missed visits (count, 
dichotomous) and visit adherence. Only 4-month visit constancy and 6-month gap had a low 
negative correlation between them (–0.126, p < 0.01). Differently from the all age group of 
PLWH+DM, the HRSA HAB measure was not correlated with 4-month visit constancy in 
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OALWH+DM. Moreover, the other variables (missed visits [count, dichotomous], visit adherence, 
6-month gap) and the HRSA HAB measure had low correlations (0.130 to 0.179, p < 0.01).  
YALWH+DM  
YA LWH+DM had a different correlation pattern than the two previous groups (see Table 
7). Missed visit (count) and missed visit (dichotomous) had a high positive correlation (0.994, 
p < 0.01). Missed visits (count, dichotomous) and visit adherence had a high negative correlation 
(–0.852, –0.853, respectively, p < 0.01). The HRSA HAB measure had a low positive correlation 
with 4-month visit constancy (0.182, p < 0.05). Except for these variables, the other measurements 
failed to significantly correlate with each other.  
Association between Retention in Care Measures and CD4 cell count  
Next, we investigated the relationship between retention in care and CD4 cell count (see 
Table 8). For OALWH+DM (n = 105), the Hosmer-Lameshow Chi-square was over 0.05, 
indicating the model fits were appropriate. The only significant relationship between retention in 
care measurements and CD4 cell count in OALWH+DM was missed visits (count) (EXP(B) = 
11.277 95% CI: 1.499-84.843, p < 0.05), which means that having more missed visits results in 
having 11.277 times higher than 500 cells/ µL CD4 cell count. However, YALWH+DM (n = 34), 
no significant association occurred between retention in care measurements and CD4 cell count at 
p < 0.05 (Hosmer-Lameshow Chi-square p > 0.05).  
Association with HIV Symptom Burden and Retention in Care  
For the whole sample (N = 501), the association between HIV symptom burden and 
retention in care (HRSA HAB measure) investigated at the significant level p < 0.05 (see Tables 
9 and 10). There were no significant relationships between HIV symptom burden and retention in 
care in YALWH+DM (N = 153; p < 0.05). Conversely, OWL PLWH+DM (N = 348) had 
significantly relationships between fatigue, memory loss, and sadness and retention in care (p < 
0.05). Of OALWH+DM having less fatigue, 0.584 times (95% CI: 0.363-0.938) higher retained, 
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those with less memory loss had 0.35 times higher retained (95% CI: 0.399-1.011), and those 
having less sadness had 1.937 times higher retained (95% CI: 1.235-3.038).  
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Table 5. Spearman’s correlation coefficients in PLWH+DM in all age group  
  
Missed 
visits  
(count) 
Missed 
visits 
(dichotomous) 
Visit 
adherence 
4-month 
visit 
constancy 
6-month 
gap 
HRSA 
HAB 
measure 
Missed visits (count, range: 0-12) 1           
Missed visits (dichotomous) 0.996** 1         
Visit adherence (continuous, range: 0–1) –0.854** –0.854** 1       
4-month visit constancy (categorical, range: 0–3) 0.005 0 0.33 1     
6-month gap (dichotomous) 0.02 0.024 –0.029 –0.105** 1   
HRSA HAB measure (dichotomous) –0.141** –0.140** 0.130** 0.93* 0.169** 1 
 
** Significant at p < 0.01 
* Significant at p < 0.05 
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Table 6. Spearman’s correlation coefficients in OALWH+DM  
  
Missed 
visits  
(count) 
Missed 
visits 
(dichotomous) 
Visit 
adherence 
4-month 
visit 
constancy 
6-month 
gap 
HRSA 
HAB 
measure 
Missed visits (count, range: 0–5) 1           
Missed visits (dichotomous) 0.997** 1         
Visit adherence (continuous, range:0–1.0) –0.854** –0.855** 1       
4-month visit constancy (categorical, range: 0–3) 0.022 0.023 0.11 1     
6-month gap (dichotomous) –0.009 –0.003 –0.002 –0.126** 1   
HRSA HAB measure (dichotomous) –0.143** –0.143** 0.130** 0.05 0.177** 1 
 
** Significant at p < 0.01 
 
Table 7. Spearman’s correlation coefficients in YALWH+DM  
  
Missed 
visits  
(count) 
Missed 
visits 
(dichotomous) 
Visit 
adherence 
4-month 
visit 
constancy 
6-month 
gap 
HRSA 
HAB 
measure 
Missed visits (count, range: 0 – 12) 1           
Missed visits (dichotomous) 0.994** 1         
Visit adherence (continuous, range: 0 – 1.0) –0.852** –0.853** 1       
4-month visit constancy (categorical, range: 0–3) –0.027 –0.050 0.074 1     
6-month gap (dichotomous) 0.11 0.111 –0.123 –0.55 1   
HRSA HAB measure (dichotomous) –0.133 –0.131 0.125 0.182* 0.143 1 
 
** Significant at p < 0.01 
* Significant at p < 0.05 
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Table 8. Associations between retention in care measures and CD4 cell count (≤	500 cells/µL) among PLWH+DM by age groups 
Age group 
  
 Variables‡ 
  
B 
  
S.E. 
  
Wald 
  
df 
  
Sig. 
  
Exp(B) 
  
95% C.I. for EXP(B) 
  
Lower Upper 
OALWH+DM 
(N = 105) 
 
  
  
  
  
  
  
  
  
Missed visits (count) 2.423 1.03 5.537 1 0.019* 11.277 1.499 84.843 
Missed visits 
(dichotomous) 2.069 1.716 1.454 1 0.228 7.918 0.274 228.713 
Visit adherence 5.582 5.733 0.948 1 0.33 265.714 0.004 20153270.43 
4-month visit 
constancy 0.685 0.566 1.464 1 0.226 1.983 0.654 6.014 
6-month gap 0.407 0.864 0.222 1 0.638 1.502 0.276 8.173 
HRSA HAB measure  0.082 0.618 0.018 1 0.894 1.086 0.323 3.648 
Constant -9.479 5.378 3.107 1 0.078 0     
Total Chi-square (df), p-value: 10.421 (6), p > 0.05 
Hosmer-Lameshow Chi-square (df), p-value: 0.89 (3), p > 0.05 
YALWH+DM 
(N = 34) 
  
  
  
  
  
  
  
Missed visits (count) 10.804 16337.328 0 1 0.999 49219.776 0 . 
Missed visits 
(dichotomous) 30.158 62616.205 0 1 1 1.25186E+13 0 . 
Visit adherence 4.645 235894.115 0 1 1 104.095 0 . 
4-month visit 
constancy 0.185 1.645 0.013 1 0.911 1.203 0.048 30.251 
HRSA HAB measure  -0.849 1.465 0.336 1 0.562 0.428 0.024 7.56 
Constant -35.14 180003.341 0 1 1 0     
Chi-square (df), p-value: 7.07 (6), p > 0.05 
Hosmer-Lameshow Chi-square (df), p-value: 2.29 (4), p > 0.05 
 
* Significant at p < 0.05 
‡: Step 1a. variables: missed visits (count), missed visits (dichotomous), visit adherence, 4-month visit constancy, 6-month gap, HRSA 
HAB measure; Step 1b. variables: missed visits (dichotomous), visit adherence, 4-month visit constancy, HRSA HAB measure 
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Table 9. Association between HIV symptom burden and retention in care using logistic regression‡ in OALWH+DM (N = 348) 
HIV Symptom 
Index  
B 
  
S.E. 
  
Wald 
  
df 
  
Sig. 
  
Exp(B) 
  
95% C.I. for EXP(B) 
  
Lower Upper 
Fatigue -0.538 0.242 4.95 1 0.026* 0.584 0.363 0.938 
Memory loss -0.454 0.237 3.67 1 0.055* 0.635 0.399 1.011 
Sadness 0.661 0.23 8.284 1 0.004** 1.937 1.235 3.038 
Constant -2.352 0.301 60.891 1 0 0.095     
Chi-square (df), p-value: 50.62 (21), p < 0.01  
Hosmer-Lameshow Chi-square (df), p-value: 0.000 (8), p > 0.05  
 
‡: Used backward stepwise 
** Significant at p < 0.01 
* Significant at p < 0.05 
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Table 10. Association between HIV symptom burden and retention in care using logistic regression‡ in YALWH+DM (N = 153) 
HIV Symptom 
Index 
  
B 
  
S.E. 
  
Wald 
  
df 
  
Sig. 
  
Exp(B) 
  
95% C.I. for EXP(B) 
  
Lower Upper 
Fatigue 21.471 2068.809 0 1 0.992 2112528447 . . 
Fever -27.257 14217.655 0 1 0.998 0 . . 
Dizzy -14.589 4718.65 0 1 0.998 0 . . 
Neuropathy -22.525 3371.868 0 1 0.995 0 . . 
Memory loss -34.677 8869.15 0 1 0.997 0 . . 
Nausea 17.1 4117.812 0 1 0.997 26685542.05 . . 
Diarrhea -19.655 5441.829 0 1 0.997 0 . . 
Sadness -35.414 14638.758 0 1 0.998 0 . . 
Anxious 32.051 13009.45 0 1 0.998 8.31266E+13 . . 
Sleep problem 22.293 2720.998 0 1 0.993 4807728150 . . 
Skin problem -68.479 4640.308 0 1 0.988 0 . . 
Cough 12.576 3256.575 0 1 0.997 289590.116 . . 
Headache 15.313 6777.269 0 1 0.998 4468795.852 . . 
Loss appetite -30.357 6736.416 0 1 0.996 0 . . 
Bloating -13.457 2912.79 0 1 0.996 0 . . 
Muscle aches -17.564 2583.466 0 1 0.995 0 . . 
Sex problem -51.422 6370.456 0 1 0.994 0 . . 
Bodyfat 31.55 1967.198 0 1 0.987 5.03675E+13 . . 
Weight loss 59.982 3757.769 0 1 0.987 1.12139E+26 0 . 
Hair loss -7.246 4911.736 0 1 0.999 0.001 0 . 
Constant -98.509 3853.126 0.001 1 0.98 0     
Chi-square (df), p-value: 50.62 (21), p < 0.01  
Hosmer-Lameshow Chi-square (df), p-value: 0.000 (8), p < 1.0  
‡: Used backward stepwise  
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Retention in Care and Disease Control Paths 
We divided the full sample into age groups (OALWH+DM, YALWH+DM) for path 
analysis. For the analysis path, we used retention in care measurements (missed visit [count], 
attendance, visit adherence, 4-month visit constancy, and disease control [CD4 cell count, HbA1c 
leve]) at the significant level p < 0.05. The total PLWH+DM study sample was (N = 772, 
OALWH+DM n = 546; YALWH+DM, n = 226). Each path diagram represents path coefficients 
and squared multiple correlations in Figures 5, 6 and Table 12. Our hypothesized path model is 
presented in Figure 4, and it applies to the different age groups in PLWH+DM. 
  
 
Figure 4. Hypothesized path model in PLWH+DM. 
Retention in Care and Disease Control in OALWH+DM  
We conducted path analysis with just OALWH+DM and found that three of the 
hypothesized paths were significant (see Figure 5), and the model fit was χ2 = 0.066, df = 2, 
P = 0.968, NFI = 1.0, RMSEA = 0.00, CFI = 1.00, TLI = 1.03 (N = 546) (see Table 11). The model 
fit was quite good. Thus, we did not need to perform re-modeling. Figure 5 and Table 12 indicate 
the hypothesized paths and coefficients in OALWH+DM. For this model, the significant paths 
consisted of missed visits (count), visit adherence and 4-month visit constancy related significantly 
with CD4 cell count at significant level p < 0.05. However, between HbA1c level and missed visits 
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(count), attendance, visit adherence and 4-month visit constancy (p < 0.05) had no significantly 
relationships. Moreover, missed visits (count) and visit adherence had a significant relationship 
each other, and visit adherence and 4-month visit constancy had a significant relationship each 
other (p < 0.05). 
 
Chi-square (df) = 0.066(2) 
Probability (P) = 0.968 
Likelihood ratio (Chi-square/df) = 0.033 
NFI = 1.00 
RMSEA = 0.00 
CFI = 1.00 
TLI = 1.03 
Notes. CFI, comparative fit index; NFI. normed fit index; RMSEA, root mean square error of 
approximation; TLI, Tucker-Lewis Index 
Figure 5. Hypothesized model with path coefficients in OALWH+DM 
 
Retention in Care and Disease Control Paths in YALWH+DM  
Finally, we conducted the path analysis with the YALWH+DM, and some differences 
persisted in this group when compared to OA with LWH+DM (see Figure 6). The hypothesized 
path in the group of YALWH+DM was (χ2 = 0.066, df = 2, P = 0.968, NFI = 1.0, RMSEA = 0.00, 
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CFI = 1.00, TLI = 1.03 [N = 226]) (see Figure 6 and Table 11). Model fit was satisfied, so we did 
not need re-modeling. Path analysis indicated that missed visits (count), and visit adherence had 
significant relationships with CD4 cell count (p < 0.05). In addition, missed visits (count), 
attendance and visit adherence had significant relationships with HbA1c level in YALWH+DM 
(p < 0.05). Moreover, missed visits (count) had significant relationships with visit attendance and 
visit adherence (p < 0.05). 
 
 
Chi-square (df) = 0.066(2) 
Probability (P) = 0.968 
Likelihood ratio (Chi-square/df) = 0.033 
NFI = 1.00 
RMSEA = 0.00 
CFI = 1.00 
TLI = 1.03 
Notes. CFI, comparative fit index; NFI. normed fit index; RMSEA, root mean square error of 
approximation; TLI, Tucker-Lewis Index  
Figure 6. Hypothesized model with path coefficients in YALWH+DM  
 
 
  64 
Table 11. Model fit comparisons by age group‡ 
Age group χ2 df P NFI RMSEA CFI TLI 
OALWH+DM 0.066 2 0.968 1.0 0.00 1.00 1.03 
YALWH+DM 0.066 2 0.968 1.0 0.00 1.00 1.03 
‡: All the models are significant at p < 0.05 
Notes. χ 2. chi-square; CFI, comparative fit index; df: degree of freedome; P: probability, NFI: 
normed fit index; TLI, Tucker-Lewis Index; RMSEA; root mean square error of approximation  
 
Table 12. Standardized path coefficients by age groups 
Model Path Path coefficient p value 
OALWH+DM  Standardized effects on CD4 cell count 
Missed visits (count) –0.46*** 0.001 
Attendance –0.04 0.73 
Visit adherence –0.43** 0.002 
4-month visit constancy 0.22* 0.040 
Standardized effects on HbA1c level 
Missed visits (count) –0.02 0.89 
Attendance –0.03 0.78 
Visit adherence 0.02 0.90 
4-month visit constancy 0.024 0.84 
YALWH+DM Standardized effects on CD4 cell count 
Missed visits (count) –0.54** 0.001 
Attendance –0.20 0.26 
Visit adherence –0.50** 0.01 
4-month visit constancy –0.02 0.91 
Standardized effects on HbA1c level 
Missed visits (count) 0.72*** 0.001 
Attendance 0.32* 0.04 
Visit adherence 0.35* 0.03 
4-month visit constancy –0.17 0.23 
 
* Significant at p < 0.05 
** Significant at p < 0.01 
*** Significant at p < 0.001 
 
 
  65 
DISCUSSION 
Our study first examined differences in retention in care for PLWH of two age groups. 
OALWH+DM had significantly lower visit attendance than YALWH+DM (p = 0.01). This result 
could possibly be due to the lack of accessibility to the hospitals for OALWH+DM because OA 
are more vulnerable to lacking social supports, including living alone and lacking health 
insurance, than YA (Emlet & Farkas, 2002). Seeing this, these vulnerable factors could 
negatively affect some OALWH in that they might not go to the clinic. 
Second, our study assessed the usefulness of six retention in care measurements by age 
groups. Spearman’s correlation coefficients analysis revealed the correlations among retention in 
care measurements in PLWH+DM differs by age group. The 4-month visit constancy was not 
correlate with the other retention in care measurements for all age groups. This could be due to 
the fact that 4-month visit constancy was considered over the 12 months and divided by the 
shorter term (every 4 months) unlike the other measurements, so it is possible that PLWH+DM 
could not be retained in such a short-term period. But with the other retention in care 
measurements, at least either one correlated in each age group. In a previous study by Mugavero, 
Westfall, et al. (2012), all the retention in care measurements correlated significantly in PLWH, 
but that study does not consider comorbid conditions. Nevertheless, our study considered 
comorbid conditions in PLWH. Considering this, 4-month visit constancy might not be an 
appropriate measurement to PLWH with comorbid conditions.   
Third, logistic regression to investigate in association between retention in measurements 
and disease progression marker (CD4 cell count in three groups), only the missed visits (count) 
variable in OALWH+DM significantly predicted CD4 cell count, the other measurements were 
not significantly associated with CD4 cell count. These findings do not agree with previous 
research. One of the major HIV disease progression marker, VL, according to Mugavero, 
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Westfall, et al. (2012), whose study included PLWH, regardless of comorbid conditions, all the 
retention in measurements and VL suppression associated significantly, regardless of comorbid 
conditions. The reason for the difference from the previous study, it remains possible that 
patients not well-retained into care develop a comorbid condition. 
Fourth, this study examined the multi-group path analysis that affected CD4 cell count 
and HbA1c levels in PLWH+DM, as divided into two age groups. With these results, we can 
determine that the missed visits affected the CD4 cell count regardless of age and that retention 
in care is important to HIV disease control (CD4 cell count) (p < 0.05). Most of retention in care 
measurements were significantly correlated to HbA1c level for YALWH+DM, however it was 
not significant in OALWH+DM (p < 0.05). However, these results were partially consistent with 
Zuniga et al., (2016) who found that OA have better control of DM and HIV than YA. However, 
one of the main areas of DM control in PLWH, retention in care in OA, did not significantly 
correlate with HbA1c level. This result could possibly be due to the fact that DM is more self-
management disease, requires daily glucose monitoring, dietary management (Vijan, Sussman, & 
Yudkin, 2014), medication adherence (Patel, Chang, Shenolikar, & Balkrishnan, 2010), and 
OALWH+DM proved more willing to manage effectively the disease  than YALWH+DM 
(Patel et al., 2010). It could thus be possible that OALWH+DM did not rely on just retention in 
care. 
Finally, this study investigated the association between symptom burden using the HIV 
symptom index and retention in care in PLWH+DM. The OALWH+DM group sample was 348. 
Among a total 20 items in symptom burden, three symptoms (fatigue, memory loss, sadness) 
were associated significantly with retention in care (HRSA HAB measure). Nonetheless, no 
significant association occurred between symptom burden and retention in care in YALWH+DM 
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at the significant level of 0.05. Because of this, healthcare professionals need to focus more on 
OALWH+DM than YALWH+DM retention in care as a key to successful management in 
PLWH (Geng et al., 2010), and having more symptom burden affected retention in care. 
LIMITATIONS 
This study had several limitations. It consisted of only samples who visited the eight clinics 
in the CNICS network and also had missing variables. The study results might thus not be 
generalized to other populations. Also, we do not consider who died during 2015 calendar year, so 
the results could be biased. But the samples were drawn from eight clinics across the United States, 
and the sample was large, so our study has representative results. In addition, missing data for CD4 
cell count and HbA1c level caused a statistical analysis bias. Prospective studies are necessary to 
provide better samples regarding CD4 cell count and HbA1c level trajectories in PLWH+DM.  
CONCLUSION 
We conducted a comparison analysis of retention in care in PLWH+DM divided by two 
age groups at a large national cohort study over one calendar year. The CD4 cell count affected 
retention in care measurements regardless of age groups. Nonetheless, HbA1c level was 
significantly affected by YALWH+DM group. The symptom burden negatively affected the 
retention in care in OALWH+DM. This is the first study considered by PLWH+DM depending on 
age groups. Even though our study contained a small number of CD4 cell count and HbA1c level 
data, these results could be a milestone to research on PLWH+DM in the future. 
ACKNOWLEDGEMENTS 
The CNICS is an NIH-funded program (R24 AI067039) made possible by the National 
Institute of Allergy and Infectious Diseases (NIAID) and the National Heart, Lung, and Blood 
Institute (NHLBI). The CFAR sites involved in CNICS include the University of Alabama at 
Birmingham (P30 AI027767); University of Washington (P30 AI027757); University of 
California, San Diego (P30 AI036214); University of California, San Francisco (P30 AI027763); 
  68 
Case Western Reserve University (P30 AI036219); Johns Hopkins University (P30 AI094189, 
U01 DA036935); Fenway Health/Harvard (P30 AI060354); and the University of North Carolina 
at Chapel Hill (P30 AI50410). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  69 
Chapter Four: Comparing 10-year Survival Rates in Comorbid Conditions in 
HIV-infected People Treated with Combined Antiretroviral Therapy (2006—
2015) 
ABSTRACT 
Background/Objectives: Diabetes (DM) is the second most common comorbid condition in 
persons living with human immunodeficiency virus (HIV) (PLWH). Also, chronic kidney disease 
(CKD) is highly related to the mortality rate. DM is one of the most major risk factors in CKD. 
The purpose of this study is to investigate the CKD occurrence rates in PLWH and PLWH+DM, 
and to calculate the survival rates in each group (PLWH, PLWH+DM, PLWH+DM+CKD) as well 
as age at initial clinic visit (≤ 30, 31-50, > 50 years old). 
Methods: This study is a secondary data analysis using the Centers for AIDS Research (CFAR) 
Network of Integrated Clinical Systems (CNICS), which included HIV-infected people. This study 
is a retrospective longitudinal comparison study in 2006 to 2015 years’ period. We divided the 
sample into three disease groups (PLWH, PLWH+DM, PLWH+DM+CKD) and age at initial 
clinic visit by using the descriptive statistics. Then we compared survival analysis for the three 
disease groups and at age at initial clinic visit using Kalan-Meier analysis and Cox regression.   
Results: Among a total of 10,063 HIV-infected participants, 8,266 people had HIV-infection only 
without any comorbid conditions, 1,720 had PLWH+DM without CKD, and 57 people had 
PLWH+DM+CKD. No participants had CKD only in PLWH. In PLWH-only, the mortality rate 
was only 3.6%, a rate almost three times higher (12.0%) in PLWH+DM than in PLWH-only, and 
a PLWH+DM+CKD mortality rate occurred at three times higher (36.8%) than PLWH+DM. The 
overall survival time mean was 19.689 years (95% CI: 19.572-19.806). However, an increased age 
at initial clinic visit resulted in reduced survival time.  
Conclusion: CKD always accompanies DM in PLWH. The survival time increased for those who 
have only HIV infection as opposed to those who have at least one comorbid conditions. This 
study indicated that mortality rates increased by comorbid conditions. This study will contribute 
to guide in survival rates in PLWH with comorbid conditions.  
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Key words: ART, chronic kidney disease, comorbid conditions, diabetes, HIV, mortality, survival 
rates 
 
INTRODUCTION 
More than one million Americans have Human Immunodeficiency Virus (HIV) (CDC, 
2017b). Currently, the mortality rates in those with PLWH in the United States was 4.7 per 100,000 
population in 2014 (CDC, 2016). With the significantly development of combined antiretroviral 
therapy (cART) since the mid of 1990s (Arts et al., 2012), persons living with HIV (PLWH) are 
approaching the life expectancy of the general population (Lewden et al., 2012; Weber et al., 
2013). The non-acquired immunodeficiency syndrome (AIDS)-related mortality rates has 
increased more than in previous years (Weber et al., 2013).  
Approximately 60% of PLWH over 50 years old have at least one comorbid condition 
(Rolls et al., 2014). Diabetes (DM) is the second-most-common comorbid condition in PLWH 
(Brown et al., 2005; Butt et al., 2009; Medapalli et al., 2012). The reason for this is that HIV-
infection causes disease inflammation through the secretion of pro-inflammatory cytokines, which 
affected damage CD4 cell count (Appay & Sauce, 2008; Decrion, Dichamp, Varin, & Herbein, 
2005) and cARTs increase DM (Smith et al., 2014). 
PLWH had three times higher chance to have chronic kidney disease (CKD) than the 
general population (Bonjoch et al., 2014; Ibrahim et al., 2012; Islam et al., 2012; Schwartz et al., 
2005). DM is one of the major risk factors of CKD in PLWH (Estrella & Fine, 2010). DM increases 
systematic inflammation (Hadigan et al., 2001) with increased insulin resistance (Hotamisligil et 
al., 1996) to destructed nephrons, and/or functional units of the kidney (Naftalin et al., 2011). 
Forty-five percent of population of CKD progress to end-stage renal disease (ESRD) (Gilmore, 
2006; Whaley-Connell et al., 2009), which is irreversible kidney damage (Bickel et al., 2013). 
People with ESRD requires dialysis, which highly correlates with mortality rates in PLWH 
(Adedeji et al., 2015; Kim et al., 2011; Szczech et al., 2004). Among PLWH+CKD patients, at the 
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ESRD stage, only 33% survive after five years with dialysis (Soleymanian et al., 2006) as opposed 
to 35% in general population after five years with dialysis (Collins et al., 2014). Thus, regardless 
of the reduction of the mortality rates in PLWH, it remains important to investigate the survival 
rates in comorbid conditions in PLWH. Nevertheless, no study exists that relates to the 
comorbidities of CKD and HIV.  
This study had two purposes. First, it sought to investigate the CKD occurrence rates in 
PLWH, and PLWH+DM in 10-year clinical periods. Second, it sought to assess the survival rates 
in each group (PLWH, PLWH+DM, PLWH+DM+CKD).   
METHODS 
Study Setting and Participants 
We conducted a retrospective chart review of a longitudinal comparison study using 
multisite national HIV cohort data from the Centers for AIDS Research (CFAR) Network of 
Integrated Clinical Systems (CNICS). The samples were over 18 years old and receiving cART 
for over six months, and visited at least one of the eight CNICS clinics located at Case Western 
Reserve University, University of Alabama at Birmingham, University of California San 
Francisco, the University of Washington, the University of California San Diego, Fenway 
Health/Harvard University, University of North Carolina Chapel Hill, and Johns Hopkins 
University. For this study, we extracted from the medical records in CNICS in 2006—2015 of 
people who visited at least one time during the study period. This study was exempted from by the 
Institutional Review Board (IRB) at the University of Texas at Austin. 
Disease verification and Mortality ascertainment 
Diagnosis of DM was defined as people who have a HbA1c level over 6.5% and/or who 
are taking DM medications. Diagnosis of PLWH+DM+CKD was defined using the chronic kidney 
disease epidemiology collaboration (CKD-EPI) equation, which measures kidney functions using 
the creatinine level (Stevens et al., 2009); greater than 60mL/min/1.73m2 to be considered CKD.  
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To ascertainment mortality, mortality rates data were obtained from medical record review 
from CNICS which includes mortality certification from state vital records and the National Death 
Index (NDI+). We examined survival rates in each group. 
Statistical analysis 
This study was tested as a conceptual model which was presented in Figure 2. Descriptive 
statistics were conducted including means, frequencies, standard deviation (SD), and percentage. 
Before conducting the analysis, authors assessed the accuracy of the data and excluded missing 
data. To examine the study characteristics, descriptive statistics were used. It included two age 
groups (≤	50 years old, > 50 years old), present sex, race/ethnicity (White, White-Hispanic, 
African-American, African-American Hispanic, Hispanics, and Others), HbA1c level, and CD4 
cell count in PLWH, PLWH+DM, and PLWH+DM+CKD. To examine difference in CKD 
occurrence, the researcher used the dichotomous variable (0: have CKD, 1: do not have CKD) 
among PLWH, PLWH+DM, and PLWH+DM+CKD. 
To examine survival rates of each group (PLWH, PLWH+DM, PLWH+DM+CKD) and 
divide by age at patients’ initial clinic visits, we used the Kaplan-Meier analysis. Survival time 
was based on the number of deaths per 100 person-years of follow-up time. Factors included type 
of disease (categorized as PLWH-only, PLWH+DM, PLWH+DM+CKD), age, race/ethnicity, 
present sex, CD4 cell count, HbA1c level, age at initial clinic visit, and age groups were divided 
by two groups (≤	50 years old, > 50 years old) because comorbid conditions frequently occurred 
in older adults; PLWH older adults is defined over 50 years old (Emlet, 2006; Legarth et al., 2016; 
Savasta, 2004; Webel et al., 2014). The mortality rates across groups were compared using the 
log-rank test at significant level p < 0.01 for this study. Moreover, we assessed the relationships 
between variables (two age groups, present sex, race/ethnicity, HbA1c, CD4 cell count, age at 
initial clinic visit, and disease groups) and survival rates, using Cox regression. We adjusted 
confounding factors, which included present sex, race/ethnicity, HbA1c level, CD4 cell count, age 
at initial clinic visit, and disease groups (PLWH, PLWH+DM, PLWH+DM+CKD) using a 
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backward-stepwise approach. All analyses were performed at 0.01 significant levels using the 
Statistical Package for the Social Science (SPSS) for PC version 23.0 (IBM Corp, Released 2015).  
RESULTS 
Study characteristics 
Among a total of 10,063 HIV-infected persons enrolled in the CNICS during the 2006 
through 2015, 8,266 people had HIV-infection without DM or CKD (see Table 13), 1,720 were 
PLWH+DM, and 57 people were PLWH+DM+CKD. Among group of PLWH, 69.8% were no 
more than 50 years old, 84.7% were male, and 51.3% were White. In addition, PLWH-only, 36.7% 
had no more than 500 cells/µL in CD4 cell count (n = 946). In addition, a 3.6% mortality rate 
occurred among PLWH, and 34.6% made an initial clinic visit in their 30s.  
Of PLWH+DM (N = 1,720), 74.7% were male, 74.9% were over 50 years old, and most 
of them were African American (48.9%). The dominant age at initial clinic visit was the 40s 
(38.3%). The baseline HbA1c level revealed that 54.5% were over the 6.5% level (n = 288), and 
42.2% of the baseline CD4 cell counts were no more than 500 cells/µL. Twelve percent of 
PLWH+DM group died between 2006 and 2015.  
Of PLWH+DM+CKD (N = 57), 68.4% were male, 68.4% of people were over 50 years 
old, and most of them were African American (73.7%). The age at initial clinic visit most 
frequently occurred for people in their 40s (36.8%) and 50s (28.1%). Almost 37% died from 2006 
through 2015. 
Following these descriptive statistics, we can recognize that the occurrence of comorbid 
conditions (DM, CKD) in this research increased by age; PLWH-only mostly consisted of those 
who were no more than 50 years old, but the other two groups’ (PLWH+DM, PLWH+DM+CKD) 
population mostly consisted of patients over 50 years old. Additionally, this study indicated that 
the mortality rates increased by comorbid conditions; PLWH-only had a mortality rate of only 
3.6% from 2006 through 2015, but if patients had DM with PLWH, the mortality rate was almost 
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three times higher (12.0%) than PLWH-only, and PLWH+DM+CKD mortality rate was nearly 
three times higher (36.8%) than PLWH+DM (p = 0.000).  
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Table 13. Study characteristics by disease groups (PLWH, PLWH+DM, PLWH+DM+CKD) 
 Study Characteristics 
All groups‡ 
  
N = 10,063 
  
PLWH-only‡ 
  
N = 8,266 
  
 PLWH+DM‡ 
  
 N = 1,720 
  
PLWH+DM+CKD‡ 
N = 57 
  
Pearson 
Chi-Square 
or Fisher’s 
Exact Test 
n % n % n % n %  
Gender Male 8345 82.9 7022 84.7 1284 74.7 39 68.4 0.56 
Female 1717 17.1 1263 15.2 436 25.3 18 31.6 
Intersection 1 0 1 0 0 0 0 0 
Age 
group 
> 50 years old 3842 38.2 2504 30.2 1288 74.9 39 68.4  ≤	50 years old 6221 61.8 5782 69.8 432 25.1 18 31.6 
Survival  Live 9536 94.8 7987 96.4 1513 88.0 36 63.2 0.000* 
Death 527 5.2 299 3.6 207 12.0 21 36.8 
Race/ 
Ethnicity 
White 4832 48.5 4204 51.3 616 36.0 12 21.1 0.000* 
White-Hispanic 778 7.8 640 7.8 136 7.9 2 3.5 
African 
American 
3151 31.6 2271 27.7 838 48.9 42 73.7 
African 
American-
Hispanic 
28 0.3 24 0.3 4 0.2 0 0 
Others 860 8.6 771 9.4 89 5.2 0 0 
Hispanic 310 3.1 280 3.4 29 1.7 1 1.8 
Total n 9,959    8,266   1,712        
Age at 
initial 
clinic 
visit 
10s 115 1.1 113 1.4 2 0.1 0 0 0.000* 
20s 2385 23.7 2301 27.8 82 4.8 2 3.5 
30s 3278 32.6 2866 34.6 400 23.3 12 21.1 
40s 2832 28.1 2153 26.0 658 38.3 21 36.8 
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Table 13. Continued 
 Study Characteristics 
All groups‡ 
  
N = 10,063 
  
PLWH-only‡ 
  
N = 8,266 
  
 PLWH+DM‡ 
  
 N = 1,720 
  
PLWH+DM+CKD‡ 
N = 57 
  
Pearson 
Chi-Square 
or Fisher’s 
Exact Test 
n % n % n % n %  
Age at 
initial 
clinic 
visit 
50s 1212 12.0 742 9.0 454 26.4 16 28.1 0.000* 
60s 216 2.1 104 1.3 108 6.3 4 7.0 
70s 24 0.2 7 0.1 15 0.9 2 3.5 
80s 1 0 0 0 1 0.1 0 0 
HbA1c 
level 
> 6.5 %         157 54.5     0.06 ≤	6.5 %         131 45.5     
Total n 10,063     8,266   288       
CD4 cell 
count 
> 500 cells/µL 770 62.0 599 63.3 171 57.8     0.33 
200-499 cells/µL 347 27.9 256 27.1 91 30.7     ≤	200 cells/µL 125 10.1 91 9.6 34 11.5     
Total n 1,242   946   296       
‡: Indicates the total sample size of the groups, but some variables have different sample sizes as presented on each table. 
*: Significant level at p < 0.001
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Survival analysis 
Of the 10,030 samples, 8253 were PLWH-only, 1,720 were PLWH+DM, and 57 were 
PLWH+DM+CKD. Each group’s occurrence of mortality was 266 in PLWH, 207 in PLWH+DM, 
and 21 in PLWH+DM+CKD; overall, 494 people died in our study period (see Table 14). The 
mean of PLWH survival time was 20.135 years per 100 person-years (95% confidence interval 
[CI]), 20.025-20.246), PLWH+DM survival time was 18.691 years (95% CI, 18.404-18.979), and 
PLWH+DM+CKD survival time was 15.433 (95% CI, 13.572-17.294) (p < 0.01). The overall 
mean survival time was 19.689 (95% CI, 19.572-19.806). The survival rates for each group are 
shown in Table 15, and Figure 7.  
Table 16 shows the mortality in age at initial clinic visit according to different disease 
groups. Of PLWH-only, most (n = 5,265) people were no more than 30 years old at initial clinic 
visit, and the group with the highest number of mortality was no more than 30 years old. But the 
other two groups (PLWH+DM, PLWH+DM+CKD) showed that most people died when over 30 
years old, and they were over 30 years old at initial clinic visit. 
Survival time refers to age at initial clinic visit by disease groups that indicates that when 
following age at initial clinic visit was older, the survival time was reduced regardless of disease 
groups (see Table 17). In PLWH, age at initial clinic visit occurred on those no more than 30 years, 
and we can thus assume that they can live around 20.451 years (CI: 20.341-20.56), but if age at 
initial clinic visit at over 50 years old, they might live 17.935 years (CI: 17.356-18.515). In 
PLWH+DM, if the age at initial clinic visit happened at no more than 30 years old, they might live 
19.768 years (CI: 19.404-20.132) but, if they went made an initial clinic visit at over 50 years old, 
the survival time was decreased (17.129 years, CI: 16.386-17.872). Of PLWH+DM+CKD, which 
has more than two comorbid conditions, if the age at initial clinic visit was at no more than 30 
years old, they can live around 18.271 years (CI: 16.046-20.496), but if the age at initial clinic visit 
at over 50 years old, the survival time was only 12.53 years (CI: 9.639-15.421). Further, the results 
demonstrated that if people have comorbid conditions in PLWH, their survival time is reduced; 
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the longest survival time was PLWH-only and PLWH+DM, and PLWH+DM+CKD. Figures 8 
through 10 indicate that survival time means by age at initial clinic visit by three different disease 
groups (≤	30, 31-50, > 50 years old).  
To calculate the risk factors associated with the mortality rates, we conducted Cox 
regression analysis. We controlled race/ethnicity, present sex, two age groups (≤	50 years old, > 
50 years old), baseline CD4 cell count, baseline HbA1c level, age at initial clinic visit, and disease 
groups (PLWH, PLWH+DM, PLWH+DM+CKD), which might influence to the survival rates. 
Only age at initial clinic visit and disease groups were risk factors to the survival rates at the 
significant level of p < 0.05. The group of patients with age at initial clinic visit from 31 to 50 
years had a mortality rate 2.203 times higher than those with an age at initial clinic visit of no more 
than 30 years old (p < 0.01, CI: 1.766-2.747) (see Table 18). The group with age at initial clinic 
visit of over 50 years had a 4.275 times higher mortality rate than the group whose age at initial 
clinic visit was no more than 50 years old at the significant level p < 0.01 (CI: 3.366-5.428). 
Between disease groups, PLWH+DM group had a 1.787 times higher mortality rate than the 
PLWH-only (p < 0.01, CI: 1.47-2.172), and PLWH+DM+CKD had a 4.739 times higher mortality 
rate than the PLWH-only (p < 0.01, CI: 3.016-7.446). 
 
Table 14. Occurrence of mortality in each group 
 Dx categories 
Total N 
  
N of deaths 
  
Censored 
  
N Percent 
PLWH-only 8,253 266 7,987 96.80% 
PLWH+DM 1,720 207 1,513 88.00% 
PLWH+DM+CKD 57 21 36 63.20% 
Overall 10,030 494 9,536 95.10% 
Notes. censored; persons still survive at that point of the study, Dx; diagnosis  
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Table 15. Survival time means according to disease categories 
Dx categories Mean 95% Confidence Interval 
Estimate Std. Error 
Lower Bound Upper Bound 
PLWH-only 20.135 0.056 20.025 20.246 
PLWH+DM 18.691 0.147 18.404 18.979 
PLWH+DM+CKD 15.433 0.949 13.572 17.294 
Overall 19.689 0.06 19.572 19.806 
Note. Dx; diagnosis  
 
Table 16. Distribution of age at initial clinic visit and occurrence of mortality 
Age at 
initial clinic 
visit 
Dx categories Total N N of deaths Censored 
N Percent ≤	30 PLWH-only 5,265 108 5,157 97.90% 
PLWH+DM 484 40 444 91.70% 
PLWH+DM+CKD 14 4 10 71.40% 
Overall 5,763 152 5,611 97.40% 
31-50 PLWH-only 2,145 97 2,048 95.50% 
PLWH+DM 658 77 581 88.30% 
PLWH+DM+CKD 21 9 12 57.10% 
Overall 2,824 183 2,641 93.50% >	50 PLWH-only 843 61 782 92.80% 
PLWH+DM 578 90 488 84.40% 
PLWH+DM+CKD 22 8 14 63.60% 
Overall 1,443 159 1,284 89.00% 
Overall Overall 10,030 494 9,536 95.10% 
Notes. censored; persons still survive at that point of the study, Dx; diagnosis  
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Table 17. Survival time means by age at initial clinic visit by disease categories 
Age at 
initial 
clinic 
visit 
Dx categories Mean 95% Confidence 
Interval Estimate Std. Error 
Lower 
Bound 
Upper 
Bound ≤	30 PLWH-only 20.451 0.056 20.341 20.56 
PLWH+DM 19.768 0.186 19.404 20.132 
PLWH+DM+CKD 18.271 1.135 16.046 20.496 
Overall 20.292 0.059 20.177 20.407 
31-50 PLWH-only 19.728 0.143 19.448 20.008 
PLWH+DM 18.819 0.226 18.375 19.263 
PLWH+DM+CKD 14.744 1.357 12.084 17.404 
Overall 19.249 0.129 18.996 19.503 >	50 PLWH-only 17.935 0.296 17.356 18.515 
PLWH+DM 17.129 0.379 16.386 17.872 
PLWH+DM+CKD 12.53 1.475 9.639 15.421 
Overall 17.734 0.266 17.212 18.256 
Overall Overall 19.689 0.06 19.572 19.806 
Notes. Dx; diagnosis  
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Figure 7. Kaplan-Meier survival curves for all-cause mortality among patients classified by all 
age disease group (PLWH, PLWH+DM, PLWH+DM+CKD), log rank p < 0.01 
Notes. censored; persons still survive at that point of the study, Dx; diagnosis  
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Figure 8. Kaplan-Meier survival curves for all-cause mortality among patients classified as	≤	30 
years old at initial clinic visit, log rank p < 0.01 
Notes. censored; persons still survive at that point of the study, Dx; diagnosis  
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Figure 9. Kaplan-Meier survival curves for all-cause mortality among patients classified as 31-50 
years old at initial clinic visit, log rank p < 0.01 
Notes. censored; persons still survive at that point of the study, Dx; diagnosis 
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Figure 10. Kaplan-Meier survival curves for all-cause mortality among patients classified as	over 
50 years old at initial clinic visit, log rank p < 0.01 
Notes. censored; persons still survive at that point of the study, Dx; diagnosis 
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Table 18. Risk factors in mortality rates 
Criteria 
Risk factors B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
Lower Upper 
Age at 
initial 
clinic visit 
≤	30 years old    142.283 2 0.000    
31-50 years old  0.79 0.113 49.11 1 0.000 2.203 1.766 2.747 >	50 years old 1.453 0.122 142.097 1 0.000 4.275 3.366 5.428 
Dx 
categories 
PLWH-only   64.946 2 0.000    
PLWH+DM 0.58 0.1 34.009 1 0.000 1.787 1.47 2.172 
PLWH+DM+CKD 1.556 0.231 45.557 1 0.000 4.739 3.016 7.446 
Note. Dx: diagnosis
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DISCUSSION 
DM and CKD in PLWH negatively impact survival rates. There were no people who do 
not have CKD without DM in PLWH in this study. These results were to be expected. Because, as 
previous study indicated that DM is a risk factor for CKD in PLWH (Estrella & Fine, 2010). 
Comorbid conditions in PLWH increased with age, having DM occurs more frequently in African 
Americans, and the mortality rate increases with age (CDC, 2015). The survival time indicated 
that there was a significant difference between the three groups (PLWH, PLWH+DM, 
PLWH+DM+CKD) at significance level of p < 0.01. PLWH-only lived almost five years longer 
than PLWH+DM+CKD, no matter when diagnosed, and almost 1.5 years longer than PLWH+DM. 
The expected survival times were each reduced by the comorbid conditions, which concurs with 
Walensky et al. (2006) study.  
In addition, having two comorbid conditions (PLWH+DM+CKD) resulted in higher 
mortality rates and decreased expected length of survival than having only one comorbid condition 
(PLWH+DM). The study’s initial database did not capture the other possible influential factors 
such as body mass index (BMI), weight, height, or blood pressure that might affect the DM and 
CKD occurrences in PLWH. Thus, future research needs to capture possible variables to more 
accurately predict survival rates in three disease groups.  
Moreover, our finding has shown that early age at initial clinic visit has positive effects 
with a longer survival time in every disease group. It could be related to the early retention in care 
in HIV patients. If PLWH have early age at initial clinic visit, they may possibly receive retention 
in care early, which in turn could affect life expectancy. Early retention in care is a major important 
success to manage HIV (Geng et al., 2010) because early retention in care positively affects viral 
load suppression and controls CD4 cell count, which protects against the development of AIDS 
(Horstmann et al., 2010; Mugavero, Amico, et al., 2012; Mugavero et al., 2010). As a result, it 
could be possible that early age at initial clinic visit affects survival time in PLWH. 
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In addition, findings also indicate that having CKD causes an increase in mortality rates 
for PLWH. There were more than four times higher mortality rates in PLWH with multiple 
diseases than those with a single disease. CKD is a dysfunction of the kidneys, and most of people 
will go to the ESRD stage, which correlates highly with mortality rates (Adedeji et al., 2015; Kim 
et al., 2011; Szczech et al., 2004).	Thus, it is important to prevent CKD in PLWH.  
LIMITATIONS AND FUTURE RESEARCH 
Although this study has a large sample size, some limitations exists. First, each group 
population is different, especially with PLWH+DM+CKD. PLWH+DM+CKD had a small portion 
population as compared to the other two groups (PLWH, PLWH+DM). Thus, this circumstance 
might have bias in our study. However, the mortality rate was highest in this group as compared 
to the other two groups. Therefore, despite this study having some bias, it remains important. In 
future studies, researchers will need a larger sample of PLWH+DM+CKD to be more accurate. In 
addition, this study is a secondary database analysis, so it might have missing data and/or incorrect 
data entered from the initial data. Also, we do not know the initial date of patients’ HIV diagnosis 
date, so, it might be biased to predict the survival rates. But this study used age at initial clinic 
visit, which in turn related in early retention in care. This study will thus contribute to retention to 
the literature in care and survival rates in PLWH with comorbid conditions. As a result, there could 
be unintentional bias to our study. Despite this, if we have or do not have missing or incorrect data 
entered in the initial data set, we have enough population portions to complete an analysis in our 
study, which could make the study come across as generalizing. Finally, during our study period, 
2006 through 2015, most data have a large censored data, so there might be bias on calculating on 
the survival rate on our study, but the SPSS captured the censored data on each disease group.  
CONCLUSION 
We conducted an analysis of survival rates in PLWH, PLWH+DM, and PLWH+DM+CKD 
divided by age at initial clinic visit from 2006 through 2015. After adjusting confounding 
variables, we found that having a younger age at initial clinic visit results in having longer survival 
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time, regardless of group. Moreover, having comorbid conditions in PLWH usually led to 
decreased survival time than only having HIV infections. Thus, our study indicated that age at 
initial clinic visit and having comorbid conditions in PLWH affects the mortality rates in PLWH. 
Based on our knowledge, there is no study to compare the survival rates among PLWH, 
PLWH+DM, and PLWH+DM+CKD, so this study will contribute considerably to future studies 
on PLWH comorbid conditions.  
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Chapter Five: Discussions, Implications, and Conclusion 
This chapter includes a study overview, conceptual model development and provides 
findings and discussions, implications and recommendations, and conclusion. Specifically, an 
overview of the purpose of the study, research questions, the methodology, a statistical analysis, 
and findings are presented. Finally, a discussion of the findings followed by research questions; a 
discussion of strengths and limitations; and recommendations for nursing practice, future research, 
nursing education, and health policy are presented.  
STUDY OVERVIEW 
Over one million people have become afflicted with an HIV infection in the United States 
(CDC, 2017b), and 60% of persons living with human immunodeficiency virus (HIV) (PLWH) 
have comorbid conditions (Goulet et al., 2007). Diabetes (DM) is the common comorbid condition 
in PLWH (Brown et al., 2005; Butt et al., 2009; Medapalli et al., 2012), and it is the main cause of 
chronic kidney disease (CKD (Estrella & Fine, 2010), which closely relates with increasing 
mortality rates (Adedeji et al., 2015; Kim et al., 2011; Szczech et al., 2004). As such, is the need 
has emerged to study PLWH with comorbid conditions. These studies are a secondary data analysis 
using the Center for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS) 
data, which include human immunodeficiency virus (HIV) infected people who are over 18 years 
old and have been receiving combined antiretroviral therapy (cART) for more than 6 months. The 
study was designed to serve two goals. The first study goal (Aim 1) was to investigate retention in 
care measurements, to compare paths regarding their retention in care and disease control (CD4 
cell count, hemoglobin A1c [HbA1c] level), and to investigate relationships between HIV 
symptom burden and retention in care between PLWH+DM as divided by two different age 
groups. The second goal (Aim 2) is to compare the long-term health outcomes of HIV and/or DM 
disease control on kidney function PLWH and PLWH+DM in the years 2006 through 2015, as 
well as survival rates differences among PLWH, PLWH+DM, and PLWH living with DM and 
chronic kidney disease (PLWH+DM+CKD). 
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Chapter Three (Aim 1), “Retention in Care and symptom burden in Persons Living with 
HIV with Diabetes for Adults over 50” is a longitudinal retrospective cross-sectional study and 
short-term goal of HIV care for PLWH+DM. Six methods are used to measure retention in care—
missed visit (count, dichotomous), visit adherence, 4-month visit constancy, 6-month gaps in care, 
and the HRSA HAB measure (U.S. Department of Health and Human Services, 2016). The 
researchers based this study on the Mugavero, Westfall, et al. (2012) study, which indicated a ‘gold 
standard’ of retention in care measurement without considering comorbid conditions in PLWH. 
Aim 1 endeavored to investigate the retention in care measurements in PLWH+DM. This study 
gives to us the knowledge of measurements of retention in care for PLWH+DM and the different 
models of retention in care (missed visits [count], visit attendance, visit adherence, 4-month visit 
constancy) and health outcomes (disease control [CD4 cell count, HbA1c level]) between two 
groups in PLWH+DM (older adults living with HIV with DM [OALWH+DM] who are over 50 
years old) and younger adults living with HIV with DM [YALWH+DM] who are 50 years old and 
under). Additionally, this study also reveals the relationships between HIV symptom burden and 
retention in care (the Health and Resources Services Administration HIV/AIDS Bureau [HRSA 
HAB measure]) in PLWH+DM. 
Chapter Four (Aim 2), titled “Comparing 10-year Survival Rates in Comorbid Conditions 
in HIV-infected People Treated with Combined Antiretroviral Therapy (2006–2015),” included 
the results of a study that investigated the occurrence of CKD in PLWH and PLWH+DM and 
examined the survival rates among the three disease groups (PLWH-only, PLWH+DM, 
PLWH+DM+CKD). This is a longitudinal comparison retrospective study. This study can serve 
as a guide for PLWH+DM to prevent CKD and increase the survival rates. There is a lack of 
current research on how the HIV/DM disease affects CKD occurrence in PLWH+DM. Moreover, 
based on this researcher’s knowledge, no survival rates of PLWH+DM+CKD have been studied. 
To be considered for inclusion in the study, all the samples were aged 18 years or older 
and had been receiving cART for at least 6 months. For Aim 1, samples also must have DM 
verified by a HbA1c level > 6.5 % or have DM medications, and researchers only considered 
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participants who had at least one primary HIV-care appointment at a CNICS clinic site during the 
2015 calendar year. For Aim 2, samples having PLWH and/or having comorbid conditions (DM, 
CDK) must have made at least one primary HIV-care visit to CNICS clinic sites in the 2006–2015 
calendar years.   
Demographic measures included age, present gender, race/ethnicity, CD4 cell count, and 
HbA1c level. For Aim 1, retention in care measurements included missed visits, visit adherence, 
visit attendance, and visit consistency (4-month visit constancy, 6-month gap, HRSA HAB 
measure) during 2015, and outcome variables were measured by disease control (CD4 cell count, 
HbA1c level). For investigating symptom burden and retention in care, this study used the HIV 
Symptom Index, which included 20-items for symptom burden and the HRSA HAB measure to 
retention in care. For Aim 2, CKD occurrence was measured by different disease groups in 2006–
2015. To measure survival rates, the researchers placed samples into different groups by disease 
(PLWH, PLWH+DM, PLWH+DM+CKD) and age at initial clinic visit in from 2006 through 
2015. 
To answer the research questions, descriptive statistics, Spearman’s correlation 
coefficients, logistic regression, path analysis, survival analysis, and cox regression were 
performed for data analysis using SPSS version 23.0 for PC (IBM Corp, Released 2015), and 
AMOS version 23.0 for PC (Arbuckle, 2014). Before conducting the statistical analysis, data errors 
were checked, missing data were managed, and assumptions were checked. 
Overall, for Aim1, a total of 798 samples are in the category of PLWH+DM in 2015; 564 
were in the OA group, and 234 were in the YA group. Most of the retention in care measurements 
were significantly correlated (p < 0.05), but 4-month visit constancy was not. Through the logistic 
regression, there were few relationships in retention in care measurements and CD4 cell count in 
OALWH+DM and YALWH+DM (p < 0.05) emerged. Only missed visits (count) variable was 
related to CD4 cell count in OALWH+DM (p < 0.05). As to paths analysis, OALWH+DM 
retention in care measurements related with the CD4 cell count only (p < 0.05); however, 
YALWH+DM related significantly with HbA1c level and CD4 cell count at a level of p < 0.05. 
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For symptom burden, no relationships existed between symptom burden and retention in care in 
YALWH+DM, but some of the symptoms that burdened patients (fatigue, sadness, memory loss) 
had a significantly negative relationship with retention in care (HRSA HAB measure) in 
OALWH+DM (p < 0.05). For Aim 2, 8,266 samples were in the PLWH category; 1,720 were 
categorized as PLWH+DM; and 57 were categorized as PLWH+DM+CKD during 2006 through 
2015. The findings indicate that CKD always occurs in conjunction with DM in PLWH (e.g., CKD 
does not occur in PLWH without DM); having more comorbid conditions decreased survival time; 
and samples’ survival time appeared lower when their initial clinic visit took place later and their 
age was higher (p < 0.01). The specific findings are described in the Findings and Discussion 
section.  
CONCEPTUAL MODEL DEVELOPMENT 
This study tested two conceptual models as there were no previous studies regarding 
retention in care in PLWH+DM. Thus, the Aim 1 model was based on the Mugavero, Westfall, et 
al. (2012) study, which presented the ‘gold standard’ retention in care measurements for PLWH 
without considering comorbid conditions. Mugavero, Westfall, et al. (2012) study suggested 
measurements including missed visits (count, dichotomous), visit adherence (continuous), 4-
month visit constancy, 6-month gap, and the HRSA HAB measure. The study used the same model 
in PLWH+DM because the Mugavero, Westfall, et al. (2012) study had already tested the 
correlations between retention in care measurements. However, for our PLWH+DM group, the 4-
month visit constancy showed no correlation between retention in care measurements (p < 0.05). 
Also, the Mugavero, Westfall, et al. (2012) study used health outcomes in the viral load, but this 
study used CD4 cell count and HbA1c level based on the disease differences. Furthermore, this 
study demonstrated the path analysis, which is not currently in research. This study demonstrated 
the different relationships between retention in care and health outcomes by different age groups 
in PLWH+DM. For Aim 2, the literature review served as basis for a conceptual model. 
PLWH+DM had more chances to have CKD according to previous studies (Estrella & Fine, 2010). 
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Thus, this study built the conceptual model for CKD occurrences in different disease groups 
(PLHW, PLWH+DM) and figured out the survival rates for the different disease groups (PLWH-
only, PLWH+DM, PLWH+DM+CKD). The finding recognized that DM is a major risk factor for 
CKD in PLWH, and survival rates were affected by comorbid conditions and aging (p < 0.01). 
These findings are significantly important because there were no studies related by survival rates 
on different disease groups in PLWH, especially on DM or CKD. But to expand on this research, 
future studies need larger samples and more particularized research regarding comorbid conditions 
in PLWH. 
FINDINGS AND DISCUSSION 
This section describes study characteristics according to the research questions and divided 
by the aims. It includes study sample characteristics, retention in care measurements, CKD 
occurrences, and survival rates for different groups.  
Findings Regarding Research Questions 
Aim 1 
Aim: Describe the population of OALWH+DM who visited the CNICS clinics during 
2015.  
Research question 1: What are the differences in demographic descriptive characteristics 
(age, gender, race/ethnicity) and baseline disease control (CD4 cell count, HbA1c level) between 
OALWH+DM (> 50 years old) and YALWH+DM (≤	50 years old)? 
Research question 2: What are the differences in retention in care descriptive 
characteristics (missed visits, visit adherence, 4-month visit constancy, 6-month gap, HRSA HAB 
measure) between OALWH+DM (> 50 years old) and YALWH+DM (≤	50 years old)? 
 
• Age. OALWH+DM mean age was 59.35 years±7.22, and the mean age of the 
YALWH+DM was 44.56 years	±5.10.  
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• Gender. Both groups have more male participants than female (OALWH+DM: 
80%, YALWH+DM: 71.4%) (p = 0.01). Of OALWH+DM, 20% were female and 
of YALWH+DM, 28.6% were female (p = 0.01). 
• Race/Ethnicity. Of OALWH+DM, 45.2% were White-Non-Hispanic, but 31.2% 
was White-Non-Hispanic in YALWH+DM (p = 0.001). The most common 
race/ethnicity in YALWH+DM was African American-Non-Hispanic (45.3%), but 
only count 38.2% of OALWH+DM (p = 0.001).   
• HbA1c level: More than half of the participants in both groups indicated that they 
have a HbA1c level higher than 6.5% (OALWH+DM: 64%, YALWH+DM: 65%). 
Still, no significantly difference in HbA1c level in either group occurred. 
• CD4 cell count: OALWH+DM uncontrolled CD4 cell count levels (CD4 cell count 
of less than 499 cells/µL) were 32.5%, and YALWH+DM was 30.2%. Nonetheless, 
no significant difference existed between the two groups. 
• Missed visits. YALWH+DM had a missed visits range was 0-12, and 
OALWH+DM was 0-5. Both groups had a mean number of visits at around three 
times during one year, which meets the Panel on Clinical Practices for Treatment 
of HIV Infection (2017) recommendation for HIV care. Despite this, no significant 
differences appear between the two groups. 
• Visit adherence. Only 6% of participants in either group had less than 50% visit 
adherence, which was correlated with visit attendance rates. Thus, most 
PLWH+DM had good visit adherence during the 2015 calendar year. 
• 4-month visit constancy, 6-month gap, HRSA HAB measure. YALWH+DM 
had better 4-month visit constancy was 31% and OALWH+DM was 28.2%. 39.2% 
of YALWH+DM had 6-month gaps (not retained), and 6.8% of OALWH+DM had 
6-month gaps (not retained). In the HRSA HAB measure, 33.7% of YALWH+DM 
had not retained and 29.9% of OALWH+DM had not retained. However, there is 
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no significantly differences among 4-month visit constancy, 6-month gap, and the 
HRSA HAB measure between two groups. 
• In sum, the significantly differences in both groups at p < 0.05 level was gender, 
race/ethnicity, visit attendance. The other variables were not significantly different 
in both groups. 
 
Research question 3: What are the correlations between retention in care measurements 
(missed visits [count, dichotomous]), visit adherence, 4-month visit constancy, 6-month gap, HRSA 
HAB measure), and each other between OALWH+DM (> 50 years old) and YALWH+DM (≤	50 
years old)?  
Research question 4: What are the relationships between retention in care measurements 
(missed visits [count, dichotomous]), visit adherence, 4-month visit constancy, 6-month gap, HRSA 
HAB measure) and CD4 cell count between OALWH+DM (> 50 years old) and YALWH+DM (≤	50 years old)?  
In this study, the below variables were significantly correlated in YALWH+DM. 
• Missed visits (count), missed visits (dichotomous) and visit adherence variables 
were highly negatively correlated to one another (–0.852, –0.853, respectively, p < 
0.01).  
• Missed visits (count) and missed visits (dichotomous) were highly positively 
correlated (0.994, p < 0.01). This result was expected because missed visits (count) 
and missed visits (dichotomous) were the same variable, just presented differently. 
In this study, the below variables had no significant or low significant correlations in 
YALWH+DM. 
• 4-month visit constancy and 6-month gap had no significant correlation between 
missed visits (count, dichotomous) and visit adherence at a significance level of 
p < 0.05. Only 4-month visit constancy and the HRSA HAB measure had a low 
positive correlation (0.182, p < 0.01).  
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In this study, the below variables had significant high correlations in OALWH+DM. 
• As with the YALWH+DM group, the missed visits (count) and missed visits 
(dichotomous) variables were highly positively correlated with each other (0.997, 
p < 0.01), and visit adherence and missed visits measurements were highly 
negatively correlated with missed visits (count; –0.854, dichotomous; –0.855) at a 
significance level of p < 0.01. 
 
In this study, the below variables had no significant or low significant correlations in 
OALWH+DM. 
• However, OALWH+DM had different results on the HRSA HAB measure. The 
HRSA HAB measure had no significant correlation with 4-month visit constancy, 
which is the opposite result from the YALWH+DM group. 
• Both of 4-month visit constancy, 6-month visit gap had not significantly correlated 
with missed visits (count, dichotomous) variables. 
• Missed visits (count, dichotomous), visit adherence, 6-month gap, and HRSA HAB 
measure had low correlations in OALWH+DM (0.130 to 0.179, p < 0.01).  
 
In this study, the below section describes the association between retention in care 
measurements and CD4 cell count. 
• There are no significant relationships in YALWH+DM between retention in care 
measurements and CD4 cell count. Except missed visits (count), there is also no 
significant relationships between retention in care measurements and CD4 cell 
count in OALWH+DM (Exp (B) = 11.277, confidence intervals [CI]: 1.499-84.843, 
p < 0.05). 
• For this research question’s majority of findings, there was no significant 
relationships between retention in care and CD4 cell count in OALWH+DM and 
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YALWH+DM at the significant level of p < 0.05. This research question need more 
future study because the previous study (Mugavero, Westfall, et al., 2012), which 
did not consider that the comorbid conditions in PLWH showed that viral load (VL) 
and retention in care had a significant relationships with each other.  
• Overall, these correlations for both PLWH+DM age groups do not match with the 
findings of Mugavero, Westfall, et al. (2012). In the Mugavero, Westfall, et al. 
(2012) study, which suggested a gold standard retention in care measurements in 
PLWH, all the retention in care measurements were highly correlated with one 
another. However, this study which considered comorbid conditions in PLWH, not 
all retention in care measurements were significantly correlated with the other 
retention in care measurements in either different PLWH+DM age groups. Thus, 
we need to redefine retention in care measurements for PLWH+DM. 
 
Research question 5: What are the differences paths in retention in care regarding HIV 
disease control (CD4 cell count) and DM disease control (HbA1c level) between OALWH+DM 
(> 50 years old) and YALWH+DM (≤	50 years old)? 
The following sections describe the path relationships between independent variables 
(missed visits [count], visit attendance, visit adherence, 4-month visit constancy), and disease 
control (CD4 cell count, HbA1c level). 
• OALWH+DM. The three hypothesized paths related significantly with CD4 cell 
count (p < 0.05): missed visits (count); visit adherence; and 4-month visit 
constancy. Missed visits (count) had a negative relationship with CD4 cell count (–
0.46), as did visit adherence (–0.43), while 4-month visit constancy had a positive 
effect on CD4 cell count (0.22) within significance level of p < 0.05. But visit 
attendance did not significantly relate with CD4 cell count (p < 0.05). Still, all the 
paths demonstrated that there were no relationships between retention in care 
measurements and HbA1c level in OALWH+DM. These findings could be the 
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result of the fact that it is simply true that retention in care is not related to HbA1c 
level in OALWH+DM. Nevertheless, the results demonstrated that retention in care 
is a key component in predicting CD4 cell count in PLWH, which is in agreement 
with previous studies (Berg et al., 2005; Hogg et al., 1998; Lima et al., 2009; 
Mugavero, Amico, et al., 2012; Mugavero, Lin, Allison, et al., 2009; Tripathi et al., 
2011; Walensky et al., 2006). 
• YALWH+DM. Four hypothesized paths related significantly with either CD4 cell 
count or HbA1c level (p < 0.05). Missed visits (count) and visit adherence had 
significant negative relationships with CD4 cell count (p < 0.05). Contrary to the 
OALWH+DM group, missed visit (count), visit attendance and visit adherence had 
significant positive relationships with HbA1c level at the significance level of p < 
0.01 (0.72, 0.32, 0.35, respectively). Despite this, 4-month visit constancy did not 
relationship with CD4 cell count or HbA1c level in YALWH+DM. These results 
demonstrate that, compared to the OALWH+DM group, YALWH+DM retention 
in care has relationships with both HIV and DM disease control, which concurs 
with the Geng et al. (2010) study. These findings are important because, through 
these results, we can see that CD4 cell count was significantly related to retention 
in care regardless of age in PLWH+DM, and if YALWH+DM had good retention 
in care, they could control both diseases.    
 
Research question 6: What are the relationships between symptom burden (HIV Symptom 
Index) and retention in care (HRSA HAB measure) between OALWH+DM (> 50 years old) and 
YALWH+DM (≤ 50 years old)?  
The following sections describe the relationships between independent variables (20-items 
in HIV Symptom Index—fatigue, fever, dizzy, neuropathy, forgetful, nausea, diarrhea, sad, 
anxious, sleep problems, skin problems, coughing, headache, loss appetite, bloating, muscle aches, 
sex problems, body fat, weight loss, and hair loss) with five response choices—0: I do not have 
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the symptom; 1: I have the symptom, but it does not bother me; 2: I have the symptom, but it 
bothers me little; 3: I have the symptom, and it bothers me some; or 4: I have the symptom, and it 
bothers me a lot (Justice et al., 2001) and retention in care (HRSA HAB measure—binary variable; 
0: not retained; 1: retained 90-days gap). 
• Three symptom burden (fatigue, memory loss, sadness) were significantly 
negatively (p < 0.05) related to retention in care in OALWH+DM (N = 348). 
Having less fatigue was 0.584 times more likely to be retained (CI: 0.363-0.938), 
decreased memory loss was 0.35 times higher retained (CI: 0.399-1.011), and less 
sadness was more than 1.937 times retained in OALWH+DM (CI: 1.235-3.038). 
Compared to the OALWH+DM, there is no significant association between 
symptom burden and retention in care in YALWH+DM (p < 0.05). The study 
findings demonstrated that fatigue, sadness, and memory loss burdens might affect 
the retention in care in OALWH+DM more than YALWH+DM. These findings are 
important for the future because, having symptom burden effect to the older 
population retention in care in PLWH.  
Aim 2  
Aim: Investigate the effect of comorbid conditions of DM and CKD on the survival rates 
of PLWH+CKD who visited the CNICS clinics from 2006 through 2015. 
Research question 1: What are the different characteristics (age, gender, race/ethnicity, 
mortality, CD4 cell count, HbA1c level) among PLWH, PLWH+DM, and PLWH+DM+CKD 
during the years 2006—2015?  
Research question 2: What is the occurrence of chronic kidney disease (CKD) among 
PLWH and PLWH+DM who visited the CNICS clinics in the years 2006—2015? 
 
The following section describes the different study characteristics and CKD occurrence by 
different groups. 
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• PLWH-only. The total number of samples in PLWH-only was 8,266 in the years 
2006 through 2015. Most of them were no more than 50 years old (69.8%), male 
(84.7%), and White (51.3%). As a baseline of CD4 cell count, 36.7% had no more 
than 500 cells/µL (n = 946), 3.6% died during the 2006—2015 time frame, and the 
age group with age at initial clinic visit was patients in their 30s (34.6%).    
• PLWH+DM. A total of 1,720 participants had PLWH+DM in 2006 through 2015. 
Most of these PLWH+DM were over 50 years old (74.9%), male (74.7%), and 
African American (48.9%). This group most commonly made an initial clinic visit 
in their 40s (38.3%). The proportion with a baseline CD4 cell count of no more than 
500 cells/ µL was 42.2%, and 54.5% had a HbA1c level over 6.5% (n = 288). Of 
the total 1,720 PLWH+DM, 12% died during the 2006—2015 time frame. 
• PLWH+DM+CKD. The samples included 57 participants. Most of them were over 
50 years old (68.4%), male (68.4%), and African American (73.7%). 
PLWH+DM+CKD most commonly went to their initial clinic visits in their 40s and 
50s (36.8%, 28.1%, respectively). Of the 57 PLWH+DM+CKD, 36.8% died in the 
2006—2015 time frame. 
• Overall, the total number of samples who enrolled in the CNICS during 2006 
through 2015 was 10,063. Among them, 1,720 PLWH had DM, and 57 people had 
DM with CKD. DM is one of the major risk factors of CKD in PLWH (Estrella & 
Fine, 2010). Furthermore, no PLWH had only CKD without DM. In addition, we 
also found that as age increases, more comorbid conditions (DM, CKD) occur in 
PLWH. These results had been predicted because incidence of chronic illness 
diseases such as DM and CKD increased with age (Mpondo, 2016; Negin et al., 
2012; Vigouroux et al., 1999; Webel et al., 2015). Among the three disease groups, 
the highest mortality rate was in PLWH+DM+CKD. This was expected because 
having CKD is highly correlated with a higher mortality rate (Adedeji et al., 2015; 
Kim et al., 2011; Szczech et al., 2004). 
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Research question 3: What is the 10-year survival rates among PLWH, PLWH+DM, and 
PLWH+DM+CKD who visited the CNICS clinics (2006—2015)? 
The following section describes the different 10-year survival rates for different disease 
groups in 2006–2015. 
• Of 10,030 people, 494 died from 2006 to 2015, and the total mean of survival time 
was 19.689 years (CI: 19.572-19.806). In PLWH-only, 5,265 people went to their 
initial clinic visits at no more than 30 years old, and the highest mortality rate group 
was those no more than 30 years of age at initial CNICS clinic visit. But PLWH 
who had comorbid conditions (DM, CKD) completed an initial clinic visit at age 
30, and the highest mortality rate group went to an initial clinic visit age at more 
than 30 years old. These results indicated that having chronic diseases occurred 
more frequently in samples of higher ages, and having more comorbid conditions 
in PLWH led to decreased survival time than without comorbid conditions in 
PLWH, which remains consistent with the Braithwaite et al. (2005) study. One 
reason could be that having comorbid conditions are possible for PLWH to have a 
symptom burden (Gay et al., 2011; Gonzalez et al., 2007) because symptom burden 
creates a negative correlation with disease control in PLWH (Gay et al., 2011; 
Gonzalez et al., 2007). The mean survival time in PLWH was only 20.135 years 
(CI: 20.025-20.246); 18.691 years (CI: 18.404-18.979) in PLWH+DM; and 15.433 
years (CI: 13.572-17.294) in PLWH+DM+CKD (p < 0.01).  
• Patients’ survival time means decreased when the age at initial clinic visit was older 
in all groups. If people were younger at initial clinic visit when they were no more 
than 30, their life expectancy would be around 20.451 years (CI: 20.341-20.56); 
however, if the age at initial clinic visit came after 50 years old, life expectancy was 
reduced by 2.516 years in PLWH-only (p < 0.01). With age at initial clinic visit at 
30 years old and under, PLWH+DM life expectancy is around 19.768 years (CI: 
19.404-20.132), but with age at initial clinic visits over 50, the life expectancy falls 
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to 17.129 years (CI: 16.386-17.872) (p < 0.01). For PLWH+DM+CKD, 18.271 
(CI: 16.046-20.496) years was the life expectancy for those whose visit age at initial 
clinic visit were no more than 30, but after turning 50, the survival time was 
significantly reduced, to 12.53 years (CI: 9.639-15.421) (p < 0.01). In addition, 
when we controlled covariate factors (race/ethnicity, present sex, age groups, 
baseline CD4 cell count, initial HbA1c level, age at initial clinic visit, disease 
groups) that could influence the survival time of each group, only the age at initial 
clinic visit affected survival time (p < 0.05). The results demonstrated that 
PLWH+DM has a higher mortality rate than PLWH-only (CI: 3.366-5.428, p < 
0.01) by 4.275 years, and the PLWH+DM+CKD mortality rate was 4.739 years 
higher than PLWH-only (CI: 3.016-7.446, p < 0.01). The reason for having lower 
survival rates in PLWH+DM+CKD than the other two groups (PLWH, 
PLWH+DM) is because mortality rates relate closely to kidney disease (Adedeji et 
al., 2015; Kim et al., 2011; Szczech et al., 2004). Forty-five percent of CKD cases 
will develop into end-stage renal disease (ESRD) (Gilmore, 2006; Whaley-Connell 
et al., 2009). The five-year survival rate is 35% in the general population (Collins 
et al., 2014), and 33% in PLWH (Soleymanian et al., 2006), and one of the risk 
factors of ESRD is an AIDS-defining illness (Abraham et al., 2014). As a result, it 
could be possible to decrease survival rates for patients having CKD than without 
CKD in PLWH.  
STRENGTHS AND LIMITATIONS 
The study has limitations. First, the study used a secondary data analysis retrospective 
longitudinal chart review from the CNICS, which might limit the generalizability of its findings 
because only the CNICS samples have been included in the studies. Second, there was missing 
data for disease control data (CD4 cell count and HbA1c level), so the results could be biased. 
Third, the CNICS data could possibly be incorrect, so the analysis could be biased based on results. 
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Last, the studies conducted a medical chart review from the CNICS data files, so they were limited 
by the variables included by the CNICS. Taking this into account, uncontrolled confounding 
factors might exist. Despite these notable limitations, the CNICS has eight clinic sites and more 
than 32,000 HIV-infected people who have been receiving cART for more than six months. Our 
findings can therefore serve as a guide to healthcare providers and PLWH.   
Even though the study had limitations, it bears important findings. The study focused on 
retention in care in PLWH+DM by different age groups, CKD occurrence, and survival rates in 
PLWH, PLWH+DM, and PLWH+DM+CKD.  
The study also had several strengths. Aim 1 addressed the comparison of retention in care 
in PLWH+DM by two age groups, making this the first study regarding comorbid conditions in 
PLWH divided into OA and YA groups. The results were significantly important because, through 
them, we can determine the significant paths and measurements between retention in care in 
PLWH+DM by different age groups. Aim 2 addressed the CKD occurrence and survival rates in 
different disease groups. This study is the first study to compare survival rates categorized by 
diseases, and this study used data from a comparatively long study period of over 10 years, so the 
results may have more representative data regarding CKD occurrences and survival rates. These 
findings will provide a good research foundation regarding developing comorbid conditions in 
PLWH.   
NURSING IMPLICATIONS AND RECOMMENDATIONS 
Implications for Nursing Practice  
Knowing that having comorbid conditions in PLWH results in poorer survival rates than 
PLWH-alone, nurses should focus on symptom control such as fatigue and neuropathy problems, 
which are common symptoms in both DM and HIV (American Diabetes Association, 2015; 
Wilson et al. 2016) to improve health outcomes. Still, this might not be enough for PLWH+DM 
because HbA1c level was not correlated with retention in care in OALWH+DM. Additional 
interventions to improve health outcomes thus become necessary, such as reducing barriers 
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including assessments, social support, and transportation. For example, nurses need to assess 
barriers of PLWH+DM the first time patients visit the clinics and introduce the connection to 
reduce the barriers. Moreover, nurses can assess patients’ transportation needs and social support. 
If the patients have barriers to transportation and social support, nurses can make connections to 
social workers or public health nurses to resolve those problems and improve health outcomes.    
Through the perspective of keeping retention in care, nurses need to assess cART side 
effect such as DM and CKD occurrence. Because DM is the main causes of CKD (Estrella & Fine, 
2010) and it is important to take care about kidney functions in PLWH, kidney disease related to 
mortality and morbidity rates after patients started in cART (Adedeji et al., 2015; Kim et al., 2011; 
Szczech et al., 2004). Among PLWH, 17% developed CKD (Post & Holt, 2009), and among them 
45% progressed to end stage renal disease (ESRD) (Gilmore, 2006; Whaley-Connell et al., 2009), 
which is highly associated with mortality and morbidity (Adedeji et al., 2015; Kim et al., 2011; 
Szczech et al., 2004). Thus, it remains important to keep monitoring kidney functions in PLWH. 
Additionally, nurses need to educate patients to keep going on to clinic (retention in care) for 
improving health outcomes because retention in care is a key management component in PLWH 
(Geng et al., 2010). Resultantly, when doctors diagnose patients with PLWH, nurses should 
educate patients that they keep going to clinics to prevent comorbid conditions, which are highly 
correlated with the mortality rates in PLWH.   
Moreover, HIV and DM require patient self-management, and patients need care at the 
community level. This study’s findings revealed that OALWH+DM with three symptom burden 
(fatigue, sadness, and memory loss) had poor health outcomes. Also, OALWH in the community 
are suffering from comorbid conditions such as DM, CKD, and depression. Despite this, a lack of 
support for PLWH with comorbid conditions in the community is apparent. One way to break 
down methods is to educate the public health nurses who are caring for PLWH closely in the 
community. Thus, in the future, we need to provide more education programs to public health 
nurses to improve health outcomes in PLWH at a community level.   
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Recommendations for Future Research 
These are some recommendations for future research based on studies findings. Although 
researchers have consistently shown the negative impact of poor retention in care on HIV health 
outcomes (Horstmann et al., 2010; Mugavero, Amico, et al., 2012; Mugavero et al., 2010), the 
study (Aim1) is the first study to examine comorbid conditions (DM and/or CKD) in PLWH. The 
findings from this study provide ample guidance for measuring retention in care in PLWH who 
have comorbid conditions. Still, most of the retention in care measurements in PLWH+DM did 
not significantly affect on the HbA1c level in OALWH+DM. Because the HbA1c level and most 
of retention in care measurements had significant relationships in YALWH+DM, the HbA1c level 
may be more influenced by other variables such as symptom burden, and medications. Future 
studies need to clarify the influencing factors on HbA1c level in OALWH with comorbid 
conditions. 
In determining the survival rates of different disease groups (Aim 2), the findings indicated 
that having CKD had the lowest survival time of the three disease groups. Also, age at initial clinic 
visit and aging had an affect on survival time. There could be more confounding factors, however, 
such as VL, medications, and length of time receiving cART, which can also affect survival rates. 
VL suppression indicated that HIV management can be conducted well by taking different 
medications (e.g., tenofovir) that have different side effects, so it could be brings to PLWH 
comorbid conditions such as DM, and the duration of receiving cART will have a positive effect 
on survival times in PLWH. To expand our knowledge of survival time for different diseases, more 
research need to be undertaken that controls possible confounding factors and includes larger 
samples. 
Recommendations for Nursing Education 
Even though a large portion of people are suffering by the HIV/AIDS infection in the U.S. 
(CDC, 2017b), there are no specific classes for the HIV/AIDS in the bachelor degree course work. 
The essentials of a baccalaureate education for professional nursing practice (American 
  106 
Association of Colleges of Nursing, 2008) indicated that baccalaureate­educated nurses need to 
prepare to care for patients of all age groups, and we need to pay more attention to OA because 
this population has more chorionic illnesses and comorbid conditions such as mental disorders. 
However, comorbidities are not addressed specially in any nursing classes taken at the bachelor 
degree level (American Association of Colleges of Nursing, 2008). Nurses need to recognize that 
comorbid conditions have more complex disease symptoms, and then they need to consider the 
side effects of any necessary medications. Comorbid conditions should therefore be added to the 
curriculum based on the increase in comorbid conditions not just in patients with HIV but in the 
aging population.   
Recommendations for Health Policy 
The vision of the National HIV/AIDS strategy released by the White House in 2015 was 
to reduce gaps in HIV care (White House Office of National AIDS Policy, 2015). One of its goals 
was to “increase access to care and improve health outcomes among PLWH” (White House Office 
of National AIDS Policy, 2015, p.9). Thus, followed by the White House Office of National AIDS 
Policy (2015), suggested the stage care system, which we called ‘the HIV care continuum’ or ‘HIV 
treatment cascade’, which involves a focus on total care of HIV-infection from diagnosis through 
achieved VL suppression. To provide appropriate care for PLWH, we need to initiate the cascade 
of care that includes optimum care for PLWH: identification of infection; linkage to initial HIV 
treatments; retention in care; and treatment adherence (Gardner et al., 2011). But the most 
important point of the HIV treatment cascade is retention in care. The high mortality rates can be 
explained in part by poor retention in care (Mugavero, Amico, et al., 2012). According to the CDC 
data, only 40% of PLWH stay in care, and 70% of PLWH in the United States in 2011 did not 
have their HIV-infection under control (Bradley et al., 2014). This reason could be followed by 
many other reasons, but one possible obstacle could be having comorbid conditions in PLWH 
because following the development of cART, OALWH had more of a chance to live longer and 
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thereby to develop chronic diseases (Negin et al., 2012) and our findings indicated that having 
more comorbid conditions affected the retention in care in OALWH. 
The Braithwaite et al. (2005) study indicated that non-HIV-induced mortality rates are 
increasing in PLWH due to them having a chronic disease, which corresponds with findings of 
survival rates: having more comorbid conditions such as DM and CKD results in having poor 
survival rates in PLWH. The researcher recommend that HIV clinics should develop a nursing 
policy of early detection of comorbid conditions in PLWH such as screening for DM and CKD. 
At some point, patients should undergo screening for HIV infections in underserved populations, 
whether they have insurance or not, to provide for the early detection of HIV and prevent 
transmission of HIV. From this point of view, the studies’ findings raise awareness of 
comprehensive retention in care and the effects of survival rates in different comorbid conditions.  
CONCLUSION 
This chapter discussed overall study findings from Chapter 3 and Chapter 4 that were 
related to the study purpose. PLWH is one of the top priorities for care needs in the United States. 
As development of HIV treatments (cART) and comorbid conditions in PLWH are steeply 
growing (Effros et al., 2008), one of the most common dual diagnoses is DM and CKD (Brown et 
al., 2005; Butt et al., 2009; Medapalli et al., 2012; Naicker et al., 2015). DM, CKD, and HIV are 
chronic conditions that are important to manage. Having a chronic disease affects a person’s 
symptom burden, and it causes poor health outcomes (Gay et al., 2011; Gonzalez et al., 2007). 
Thus, it is important to take care of comorbid conditions in PLWH. This study has two main aims: 
1) investigate retention in care measurement in PLWH and in OWLWH+DM and YALWH+DM 
and recognize the association between symptom burden and retention in care in OWLWH+DM 
and YALWH+DM; and 2) comparing CKD occurrence and survival rates in PLWH, PLWH+DM, 
and PLWH+DM+CKD. The studies demonstrate retention in care and health outcomes according 
to age group in PLWH+DM, recognize that symptom burden (fatigue, sadness, memory loss) can 
affect the retention in care in OALWH+DM, and investigate the CKD occurrence and survival 
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rates in different disease groups. The results of the studies will contribute to nursing practice, 
research, and policy to address the comorbid conditions in PLWH, especially with DM and CKD 
in PLWH. 
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